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a b s t r a c t
During our search for topically-active Caspase-1 inhibitors, we identified a novel class of potent in-
hibitors based on a 1,3,5-trisubstituted uracil motif equipped with an L-aspartate semi-aldehyde derived
warhead. In the literature, the majority of Caspase-1 inhibitors possessing the same warhead have been
designed and evaluated for oral administration as the ethyl acetal pro-drug form. For our topical pro-
gram, the pro-drug acetal form was not fully hydrolysed in the skin and was unstable in many of our
standard topical excipients, therefore, we were obliged to focus on the actual hemiacetal drug form of the
molecule during our drug discovery program. Our work focuses on both the synthesis and achiral and
chiral stability of the final drug molecules in topical excipients.
© 2018 Elsevier Ltd. All rights reserved.
1. Introduction
Caspases are a family of protease enzymes called Cysteine
Aspartic Proteinases. There are 12 known Caspases in humans.
Caspases 1, 4, 5, 11 and 12 are all inflammatory caspases and 2, 3, 6,
7, 8, 9 and 10 are all associated with apoptosis [1]. All caspase
substrates are cleaved from the C-terminus of an aspartic acid
residue C-terminal in the P1 region of the binding site. Interleukin-
1b converting enzyme (ICE), also known as Caspase-1, is the prin-
cipal enzyme responsible for cleavage and activation of pro-Inter-
leukin-1b (pro-IL-1b) to its active form IL-1b, which in turn is
involved in the pathogenesis of several inflammatory disorders
including acne vulgaris [2]. The cleavage of pro-IL-1b to IL-1b oc-
curs through deprotonation of a cysteine residue via a neighbour-
ing histidine. Cytokine IL-1b plays an important role in local and
systemic inflammation and has been reported to target numerous
cells involved in inflammatory acne [3]. In a recent study, we re-
ported a comparison of lesional versus non-lesional biopsies of
patients with inflammatory acne and through transcriptomic and
proteomic studies, we showed a strong induction of IL-1b mRNA
and IL-1b protein in lesional biopsies [4]. Consequently, the treat-
ment of inflammatory acne with a topical agent targeting Caspase-
1 presented an exciting and novel opportunity for the treatment of
moderate to severe acne.
Medicinal chemists have developed potent inhibitors of the
catalytic site principally by using masked aldehydes [5]. These form
a reversible covalent linkage with the cysteine residue to block the
enzyme from functioning. In 1992, Thornberry et al., inspired from
the actual sequence of Caspase I substrate pro-IL-1b, discovered a
tetrapeptide motif, Ac-YVAD-CHO with nanomolar potency against
Caspase I. The C-terminus of the aspartic acid residue was modified
to an aldehyde resulting in reversible covalent inhibition of the
enzyme through a hemithioacetal linkage (Fig. 1).* Corresponding author.
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To overcome the poor ADMET of the early peptidic leads, potent
peptidomimetic inhibitors of Capsase-1 [6], Pralnacasan (VX740)
and Belnacasan (VX765) were developed and have been progressed
to clinical studies for the treatment of rheumatoid arthritis and
treatment-resistant epilepsy. Inspired by their approach, we set
about designing our own cyclic peptidomimetic inhibitors based on
scaffolds while preserving the 3 point H-bonding network and the
aspartaldehyde warhead (Fig. 2) [7].
2. Results and discussion
We developed several synthetic strategies to deliver the piper-
idin-2,6-dione and pyrrolidin-2,5-dione based inhibitors that we
have already detailed in a recent communication [8], focusing
principally on: a) P1 warhead exploration; and b) probing the P4
region both exemplified in Schemes 1 and 2, respectively.
For topical medicinal chemistry, activity is always an important
driver but the solution stability of our actives is another major
consideration as the API is not formulated in solid form but in wet
form such as creams, lotions or gels [9]. The topical excipient
selected for screening purposes was a 96% w/w aqueous ethanol.
Solutions at 0.01% (w/w)weremonitored byHPLC during 3months.
Ideally, we would expect our developable candidate to have >90%
of its original peak area remaining after 3months at 40 C. This can
be extrapolated to a shelf-life over >1 yr in the final topical
formulation at room temperature [10].
Early on in our investigations, we established that the ethyl
acetal pro-drug form (eg., 8) of our final compounds was actually
less stable than the hemiacetal drug form (eg., 1 and 2) in all of our
topical excipients. Moreover, the pro-drug was also not cleaved
sufficiently quickly enough to the drug form in our in vitro and
in vivo assays. Therefore, we targeted the preparation of the drug
form of our final compounds for evaluation in our testing cascade.
Both pyrrolidin-2,5-dione and piperin-2,6-dione scaffolds 1 and
2 provided our first lead compounds with moderate activity
2400 nM and 1500 nM, respectively, against Caspase-1 (Schemes 1
and 2). However, the stability studies were very disappointing with
all of our early designs. Both drug (1, 2) and pro-drug (8) did not
achieve an acceptable level of stability (>90%) at 40 C after just
30 d and only 2 had acceptable stability with just 9% degradation at
23 C after 30 days (Fig. 2). It is also interesting to note that the drug
form 1was more stable at 40 C than the pro-drug form 8with 70%
versus 58% of the original peak remaining, respectively (Fig. 3).
By HRMS, we managed to identify the principal degradation
products of our lead piperidin-2,6-dione series being due to ring-
opening and loss of the warhead, not through hydrolysis of the
amide bond but through tautomerisation followed by alcoholysis of
Fig. 1. Binding mode of Ac-YVAD-CHO in Caspase I (Black, P4 pocket; blue P3/P2 re-
gion; red, P1 warhead region).
Fig. 2. Our design rationale for a new classes of imide-based peptidomimetic Caspase-
1 inhibitors.
Scheme 1. A representative route designed for P1 exploration and used to deliver eg.,
1. Reagents and conditions: (a) EDCI, DCM, 16 h, r.t.; (b) H-Ala-OtBu.HCl, DIPEA, 2 h, r.t.;
(c) EDCI, HOBt (1.5 eq.), 16 h, r.t., 58%; (d) 4M HCl in dioxane, EtOAc, 5 C, 16 h, quant.;
(e) 2-naphthoyl chloride, DIPEA, THF, 0 C-r.t., 4 h, 59%; (f) TFA-DCM (1:3), r.t., 6 h,
quant., (g) Pd(PPh3)4, DMBA, DCM, r.t., 15min; (h) 5 pre-activated EDCI, HOBt, DCM,
DMF, 0 C, 15min, amine from step (g) added, r.t., 16 h, 72%; (i) TFA, DCM, r.t., 59%; (j)
2N HCl (aq), MeCN, 0 C-r.t., 32%.
Scheme 2. A representative route designed for P4 exploration and used to deliver eg.,
2. Reagents and conditions: (a) K2CO3, MeCN, r.t., 53%; (b) TFA, 0 C-r.t., quant.; (c)
Pd(PPh3)4, DMBA, DCM, r.t., 15min; (d) 10 pre-activated EDCI, HOBt, DCM, DMF, 0 C,
15min, amine from step (c) added, r.t., 16 h, 62%; (e) H2, Pd(OH)2-C, EtOAc, r.t., 78%; (f)
TEA, DCM or 43%; (g) TFA, DCM, r.t., 75%; (h) 2N HCl (aq), MeCN, 0 C-r.t., 52%.
Fig. 3. Comparative stability evaluation of 1, 2 and 8.
the intermediate enamine or by a retro-Michael reaction (Fig. 4).
To overcome this stability issue of the piperidin-2,6-dione se-
ries, we decided to transpose our SAR to a 1,3,5-trisubstituted uracil
scaffold [7,11]. We anticipated that the stability issues would be
addressed by preventing ring opening and replacing the sensitive
chiral center at C3-H of the piperidin-2,6-dione unit that we had
great difficulty in controlling during the assembly of our final
products (eg., 1 and 14) [8]. The first match pair (14 v 15), incor-
porating Sunesis' quinoxaline P4 fragment [12], showed an
impressive ~40 fold gain in potency and solution stability improved
significantly, 55% v 84%, respectively. However, during the assembly
of our final molecules we encountered great difficulty to control the
stereogenic center off N-3, finishing routinely with a racemate. To
overcome this epimerization issue, we introduced a cyclopropyl
group [13]. Indeed, as discussed previously by us [7], we suspected
that it should be accommodated in the limited space in the binding
cleft between Val338 and Trp340. Moreover, after further SAR
(structure activity relationship) and SPR (structure property rela-
tionship) investigation, we identified 16 as our new lead candidate
with much improved potency, stability, photosafety and synthetic
feasibility (Fig. 5) [7].
The key step for our uracil fragments relied on a novel 3 MCR
(multi-component reaction) construction of the 5-nitrouracil
fragment (21) with a cyclopropyl moiety at N-1 described in a
recent letter [13]. From 21, alkylation at N-3 followed by reduction
using dissolving metal conditions [14] afforded the amino P2/P3
fragment 23, coupling with the optimized P4 fragment (24) using
COMU ((1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethyl-
amino-morpholino-carbenium hexafluorophosphate) [15], fol-
lowed by Alloc deprotection afforded 25. The synthesis terminated
with installation of the precyclised P1 warhead fragment 26
through a one-pot Alloc deprotection/amide coupling step followed
by hydrolysis of the pro-drug ethyl acetal 27 to afford hemiacetal 16
(Scheme 3).
Our new lead compound 16 was not only more than 150 times
more potent but also much more stable than our early designs 1
and 2 (Fig. 6) [7]. After 30 d at 40 C, only 17% degradation was
observed with compared to 50% with our first lead 1. Although we
had not achieved <10% degradation after 3months at 40 C, we
were confident that we could achieve our target value by exploring
other topical excipients. As illustrated previously (Fig. 3), the pro-
drug form (27) was also less stable than the drug form (16) with
60% versus 40% degradation observed after 3months at 40 C,
respectively.
As we moved further into lead optimisation, we prepared the
enantiomer (28) of our lead compound (16) to test its activity and
use as a standards to monitor potential chiral degradation (epi-
merization at C-3) of the P1 warhead fragment. Although the fur-
anone warhead of compound 16 has two chiral centers, the C-2-OH
epimers are rapidly interconverting through ring opening and
closing of 16-aldehyde. Consequently, at best, immediately after
Fig. 4. Major product distribution of 2 determined by LC-HRMS in 96% w/w EtOH(aq)
after heating at 40 C for 30 days.
Fig. 5. A simplified SAR and SPR evolution of the early lead based on a piperidin-2,6-
dione P2/P3 peptidomimetic scaffold to the optimized 1,3,5-trisubstituted uracil
scaffold.
Scheme 3. Principal route employed for the preparation 16 and its analogues. Re-
agents and conditions: (a) KOCN, water, reflux, yield 78%; (b) Allyl bromide, DIPEA,
THF/H2O (10:1), 60 C, 18 h, yield 68%; (c) ethyl nitroacetate, triethyl orthoformate,
toluene, reflux, yield 79%; (d) Cs2CO3, MeCN, reflux, 78%; (e) 2-iodopropane, K2CO3,
DMF, r.t., 24 h, 46%; (f) Fe(s), NH4Cl(aq), THF, EtOH-H2O, 70 C, 1 h, 98%; (g) 24, COMU,
NMM, DMF, 50 C, 48 h, 90%; (h) Pd(PPh3)4, DMBA, DCM, r.t., 45min, 60%; (i) i.
deprotection of 26, Pd(PPh3)4, DMBA, DCM, r.t., 15min; ii. pre-activation of 25 with
HATU, DIPEA, DCM-DMF, r.t., 16 h; iii. products from step i added dropwise to ii and
reaction mixture stirred at r.t., 16 h, quantitative; (j) 2M HCl (aq), MeCN, r.t., 2 h, 65%.
Fig. 6. Comparative stability evaluation of 16 versus its prodrug 25 and early piper-
idin-2,6-dione lead 2.
the hydrolysis of the pro-drug, we obtain 16 as a 1:1 mixture of
diastereomers (3S, 2RS), racemic at the hydroxyl-bearing carbon C-
2 (Scheme 4).
Both 16 and 28 were prepared separately and assayed. They
were equipotent which was surprising looking at what had been
reported in the literature, raising the question of whether epime-
rization at C-3 was occurring during hydrolysis of the pro-drug or
during storage in DMSO solution. We confirmed that epimerization
was not occurring at the hydrolysis stage either by reduction of the
aldehyde 16 to the alcohol 29 or by condensation to the benzy-
loxime 30 immediately after isolation. Therefore, epimerization
must be occurring during dissolution and storage of 16 in DMSO or
during the in vitro assay (Scheme 5).
Next, we decided to study the chiral stability of 16 in our model
excipient (96% EtOH (aq)). While we could have employed the
derivatisation methods shown in Fig. 7 to monitor chiral degrada-
tion at selected time points, we wanted to eliminate all possible
contributory factors and focused on the development of a chiral
chromatographic method.
The separationof racemic16was testedbyapreliminaryscreening
of 8 chiral columns (Chiralpak IA, IB, IC, ID, IE, IF,Whelk-O1 andUlmo)
with a mixture heptane/ethanol/chloroform (2/4/4) as the mobile
phase. Chiralpak IC, cellulose tris(3,5-dichlorophenylcarbamate)
polymer immobilized on silica, proved to be able to partially separate
the enantiomers as shown on the reported UV chromatogram
(Fig. 7a). The analytical conditions on this column were then opti-
mized. Theuseof lesspolareluent gavebroadpeaks (Fig. 7b), heptane/
ethanol binary mixtures improved the enantioselectivity but with
fronting of the 2 peaks (Fig. 7c), separation was lost with heptane/2-
propanol mixtures and enantioselectivity decreased rapidly as tem-
peraturewas increased. Finally, additionof0.5%of triethylamine in the
mobile phase allowed a baseline separation of the enantiomers with
an enantioselectivity of 1.9 and a resolution of 1.8 (Fig. 7e). We
retained these conditions to follow the chiral degradation of our final
products.
The appearance of an additional peak in the presence of TFA
(Fig. 7d) was interesting and prompted us to invest more time in
method development. We hypothesized that under this condition,
the extra peak arose from the start of the separation of the dia-
stereomeric warheads (ie., in the case of 16, 3S/2S from 3S/2R).
Further screening of different columns and a new optimisation of
the analytical conditions highlighted an exchange between
different species, as indicated by the shape of the chromatograms
(Fig. 8). In this acidic condition, at 40 C, the opened aldehyde forms
are in equilibrium with the hydroxy-furanone ring forms and all 4
diastereomers could be distinguished along with later running
peaks that we assumed to be the open aldehyde forms assigned on
the basis of mass spectrometry alone. These observations
confirmed the configurational stability of the carbon bearing the
nitrogen atom and the fast epimerization of the carbon bearing the
hydroxyl group.
With our optimized chiral chromatographic conditions in hand
(Fig. 7e), we monitored the chiral degradation of 16 in different
excipients. Routinely, in the lead optimisation phase of our drug
discovery programs, we would be expecting to achieve an e.r. of
Scheme 4. Proposed mechanism of epimerization of 16.
Scheme 5. Methods developed to test for epimerization during hydrolysis step.
Fig. 7. Chiral HPLC method development for the separation of the enantiomer of 16:
Chiralpak IC, 1mL/min, 25 C, detection UV at 330 nm.
Fig. 8. Equilibria between opened and closed warhead forms of 16 & 28 evidenced by
chromatographic profile on Chiralpak IA, 1mL/min, 40 C, detection UV at 330 nm.
95:5. As attested by the results in Table 1, racemisation was
practically complete at 40 C after just 1 d in 96% v/v EtOH (aq).
Even after 30 d of storage at 0 C, an unacceptable e.r. of 89/11 was
obtained (entry 1). Similar results were also obtained as a 0.1% w/w
solution in other commonly employed topical excipients from our
screening panel. In summary, with 16 in solution, we were unable
to significantly alter the rate of chiral degradation despite screening
a wide variety of topically-acceptable solvents under various con-
ditions (temperature, concentration, pH) [16]. Therefore, we
switched to a suspension formulation by micronizing 16 and sus-
pending the micronized solid in different media as a 1% w/v sus-
pension (entries 2 and 3). While there was little improvement in
chiral and achiral degradation in water compared to 96% EtOH (aq)
(entry 2 v entry 1), only minor degradation was observed in oil at
23 C after 3 months (entry 3) (Table 1).
With these results in hand we switched our focus back on
chemical modifications to prevent chiral degradation altogether.
The synthetic routes for the novel six-membered warheads 37e39
were very similar to those employed for the preparation of our
aspartaldehyde warhead 6 (Table 1) [17]. However, we were unable
to transpose the same methodology for the preparation of the
quaternary warhead 35 and had to change our strategy. Briefly,
Fmoc protection of commercially-available (S)-2-amino-4-(tert-
butoxy)-2-methyl-4-oxobutanoic acid (31) followed by reduction of
the carboxylic acid 32 to the alcohol through reduction of the mixed
anhydride using NaBH4. Fmoc deprotection afforded amine 33 fol-
lowed by amide coupling with 34 using HATU afforded 35. Finally,
oxidation of the alcohol using Dess-Martin periodinane (DMP) to
the aldehyde followed by deprotection of the tert-butyl protecting
group using TFA afforded 36 albeit in poor yield (Scheme 6).
Evaluation of the P1 warheads is shown in Table 2. The non-
epimerisble quaternary warhead 36 (entry 3) was inactive despite
encouraging docking studies. It is interesting to note that there is 18
fold loss of activity by switching the configuration from R (37) to S
(38) for the 6-membered non-epimerisable warhead match pairs
(entries 4 and 5). While the R warhead 37was moderately potent at
130 nM, it was unfortunatelymuch less stable than 16with only 64%
of the compound remaining after 30 d at 40 C. As the activity of our
both 5-membered warhead enantiomers (16 and 36) was identical,
was can safely assume that epimerization must be happening
readily during our assaying of 16 in the enzymatic screen (entries 1 v
2). Finally, the direct 6-membered cyclic analogue of our lead
warhead (39) was only moderately active at 560 nM.
3. Conclusion
In conclusion, we have described the synthesis and stability
evaluation of a novel class of potent peptidomimetic Caspase-1
inhibitors based around cyclic imidic central cores with the hemi-
acetal drug-form of the warhead. Our SAR and SPR exploration
Table 1
Chiral and achiral integrity study of 16 in different excipients.
Entry Excipient Conditions Chiral stability (3S,2RS/3R,2RS) Achiral stability
1 0.01% w/w in 96% EtOH (aq)a 0 C 89/11 after 30 d N/A
23 C 83/17 after 1 d >95%/6mo.
40 C 55/45 after 1 d 84%/30 d
2 1% w/wb in water 0 C >99/1 after 30 d N/A
23 C 88/12 after 1 d 83%/1mo.
40 C 55/45 after 1 d N/A
3 1% w/wb in oil Primol 352 0 C N/A N/A
23 C 95/5 after 3mo. >95%/6mo.
40 C 92/8 after 1mo. N/A
a Similar results were obtained in other common topical excipient medium including H2O, 2-propanol, propylene glycol, schercemol.
b 16 was micronized and suspended in the medium; N/A¼ not assayed.
Scheme 6. Route employed for the preparation 36. Reagents and conditions: (a) Fmoc-
OSuc, 10% Na2CO3 (aq), dioxane, r.t., 12 h, 85%; (b) IBCF, NMM, DME, 0 C, 1 h then add
NaBH4, rt, 18 h, 98%; (c) Pyrrolidine-MeCN (10% v/v), r.t., 16 h, quant.; (d) HATU, NMM,
DMF, 80 C, 4 h, 45%; (e) Dess-Martin periodinane, DCM, 0 C to r.t., 2 h, quant.; (f) 2.
TFA, DCM, rt, 1 h, 35%.
Table 2
Comparison of the hemiacetal P1 Warheads.
Entry Compound Warhead IC50 (nM) Stabilityb
1 16 10 84
2 28 10 88
3a 36 5900 79
4 37 130 64
5 38 2400 68
6a 39 560 85
a Not a direct match pair.
b Compounds were tested as 1% w/w solutions in 96% w/w EtOH (aq) at 40 C for
30 d.
drove us to identify a uracil-based P2/P3 peptidiomimetic scaffold
showing excellent potency and much improved achiral stability in
solution in our standard excipients. The chiral and achiral stability
of the hemiacetal warhead series proved to be themost challenging
aspect of our exploration. This was studied in solution and was, to
some extent, controlled through micronisation of the API and
suspension in an oil medium.
4. Experimental
1H NMR spectra were recorded on a Bruker Biospin Avance 400
spectrometer unless otherwise stated. Chemical shifts are reported
as d values downfield from internal TMS in appropriate organic
solutions. The abbreviations used for explaining the multiplicities
were as follows: s¼ singlet, d¼ doublet, t¼ triplet, q¼ quartet,
m¼multiplet, br¼ broad. For compounds isolated as mixtures of
isomers, the 1H integration is described as fractional integration
according to the ratio of isomers. High resolution mass (ESI HRMS)
was recorded on a Thermofisher Q Exactive™ Hybrid Quadrupole-
Orbitrap™ Mass Spectrometer. The relative purity and the mass of
the products were confirmed by LC/MS (220 nme420 nm) on a
Waters acquity uplc photodiode array detector system using the
following conditions: Column, BEH C18 50*2.1 mm; 1.8 mm; Solvent
A, water 0.1% formic acid or water ammonium carbonate 2 g/L;
Solvent B, CH3CN; flow rate, 0.8mL/min; run time, 2.2 min;
gradient, from 5 to 95% solvent B; mass detector, Waters SQ de-
tector. All compounds were purified by LC/MS on a waters Auto-
purification system using the following conditions: Column,
Xbridge C18 150*30 mm, 5 mm; Solvent A, water 0.1% formic acid or
water ammonium carbonate 2 g/L; Solvent B, CH3CN; flow rate,
50mL/min; run time, 10 or 15min; with adapted isocratic elution
mode; mass detector, Waters ZQ detector.
4.1. N-((3R)-1-((2S)-1-(((3S)-2-hydroxy-5-oxotetrahydrofuran-3-
yl)amino)-1-oxopropan-2-yl)-2,5-dioxopyrrolidin-3-yl)-2-
naphthamide (1) was prepared in 7 steps
4.1.1. tert-Butyl (S)-2-((R)-3-((tert-butoxycarbonyl)amino)-2,5-
dioxopyrrolidin-1-yl)propanoate (4)
To a suspension of Boc-D-Asp-OH (3, 2.0 g, 8.58mmol) in DCM
(60mL) at 0 C was added EDCI (1.98 g, 10.2mmol). The reaction
mixturewas stirred at room temperature for 1 h, cooled at 0 C then
L-Ala-OtBu.HCl (1.48 g, 8.15mmol) and DIPEA (3.0mL, 17.1mmol)
were added successively. The reaction mixture was stirred at room
temperature for 1 h 30min, cooled to 0 C then EDCI (1.98 g,
10.2mmol) and HOBt (1.28 g, 9.43mmol) were added. The reaction
mixture was stirred at room temperature for 16 h 1N HCl (aq) was
added and the mixture extracted using DCM. The organics were
washed sequentially with a saturated solution of NaHCO3 (aq), 1N
HCl (aq), brine, dried over Na2SO4, filtered and concentrated under
vacuum. The residue was purified by silica gel flash chromatog-
raphy (cyclohexane/EtOAc, gradient of 1/0 to 1/1) to give expected
product (1.72 g, 58%) as a white solid: LCMS ESIþ m/z 343 (MþH)þ,
360 (MþNH4)þ; 1H NMR (500MHz, DMSO‑d6) d 7.55 (d, J¼ 8.0 Hz,
1H), 4.62 (q, J¼ 7.2 Hz, 1H), 4.38e4.30 (m, 1H), 2.97 (dd, J¼ 17.5,
9.5 Hz, 1H), 2.60 (dd, J¼ 17.5, 6.0 Hz, 1H), 1.38 (s, 9H), 1.37 (s, 9H),
1.30 (d, J¼ 7.0 Hz, 3H).
4.1.2. tert-Butyl (S)-2-((R)-3-amino-2,5-dioxopyrrolidin-1-yl)
propanoate hydrochloride
To a solution of tert-butyl (S)-2-((R)-3-((tert-butoxy-carbonyl)
amino)-2,5-dioxopyrrolidin-1-yl)propanoate (1.0 g, 2.92mmol) in
EtOAc (20mL) at 0 C was added HCl (4 N in dioxane, 7.3mL,
29.2mmol, 10 eq.). The solution was stirred at room temperature
for 5 h then at 4 C during 15 h. The solvent and excess HCl were
removed under reduced pressure at room temperature. The residue
was taken-up in EtOAc and the solvent evaporated again to give
expected product (850mg) as beige solid. The product was engaged
directly in the following step without further purification: LCMS
ESIþ m/z 243 (MþH)þ.
4.1.3. tert-Butyl (S)-2-((R)-3-(2-naphthamido)-2,5-dioxo-
pyrrolidin-1-yl)propanoate
To a solution of tert-butyl (S)-2-((R)-3-amino-2,5-dioxopyrrolidin-
1-yl)propanoate hydrochloride (810mg, 2.91mmol) in THF (20mL) at
0 C was added 2-naphthoyl chloride (665mg, 3.48mmol) followed
with DIPEA (1.78mL, 10.2mmol). The reaction mixture was stirred at
room temperature for 4 h then hydrolysed with H2O and extracted
with EtOAc. The organic phasewaswashedwith aq.1NHCl and brine,
dried over Na2SO4, filtered and concentrated under vacuum. The res-
idue was purified by silica gel flash chromatography (cyclohexane/
EtOAc, gradientof1/0 to3/7) togiveexpectedproduct (800mg,59%)as
a beige solid: LCMS (tR¼ 3.53min, purity¼ 96%) ESIþ m/z 397
(MþH)þ, 414 (MþNH4)þ; 1H NMR (500MHz, DMSO‑d6) d 9.38 (d,
J¼ 7.5Hz,1H), 8.47 (s, 1H), 8.06e7.96 (m, 3H), 7.92 (dd, J¼ 8.5, 2.0 Hz,
1H), 7.68e7.58 (m, 2H), 4.76 (m, 1H), 4.69 (q, J¼ 7.0Hz, 1H), 3.12 (dd,
J¼ 17.5, 9.2, Hz, 1H), 2.81 (dd, J¼ 17.5, 5.2 Hz, 1H), 1.41 (s, 9H), 1.39 (t,
J¼ 7.0Hz, 3H); Chiral HPLC (Chiralpak AD, n-heptane/2-propanol (80/
20), 1mL/min., tR¼ 19.46min, purity¼ 100%).
4.1.4. (S)-2-((R)-3-(2-Naphthamido)-2,5-dioxopyrrolidin-1-yl)
propanoic acid (5)
To a solution of tert-butyl (S)-2-((R)-3-(2-naphthamido)-2,5-
dioxopyrrolidin-1-yl)propanoate (800mg, 2.02mmol) in DCM
(5mL) at 0 C was added TFA (1.55mL, 20.2mmol). The solution
was stirred at room temperature for 6 h. Then the solvent and
excess TFA were concentrated under vacuum. The residue was co-
evaporated with DCM, then with EtOAc, and dried under vacuum.
Expected product was isolated as a beige solid (690mg, quant.) and
was used without further purification.
4.1.5. tert-Butyl (S)-3-(((allyloxy)carbonyl)amino)-4,4-diethoxy-
butanoate (6) was prepared in 4 steps
Step 1: To a cooled (4 C) solution of L-aspartic acid 4-tert-butyl
ester (25.0 g, 132.1mmol) in THF/H2O (80 mL/240mL) were added
sodium bicarbonate (44.4 g, 528.5mmol) and allyl chloroformate
(25.3mL, 237.8mmol). After 2h30 of stirring at room temperature,
the medium was extracted with EtOAc (three times). The aqueous
layer was acidified with aqueous HCl (6 N) until obtaining pH 2. The
aqueous layer was extracted (EtOAc, three times). The combined
organic layer was dried over sodium sulphate, filtered and
concentrated in vacuo to afford (S)-2-(((allyloxy)-carbonyl)amino)-
4-(tert-butoxy)-4-oxobutanoic acid (29.2 g, 80%) as a pale yellow
oil: LCMS ESI m/z 272.4 (M-H)-; 1H NMR (CDCl3, 500MHz)
d 5.87e5.96 (m, 1H), 5.74 (bd, J¼ 8.5 Hz, 1H), 5.31 (m, 1H), 5.22 (m,
1H), 4.55e4.65 (m, 3H), 2.97 (dd, J¼ 17.0 Hz and 4.0 Hz, 1H), 2.76
(dd, J¼ 17.0 Hz and 5.0 Hz, 1H), 1.44 (s, 9H).
Step 2: To a cooled (4 C) solution of (S)-2-(((allyloxy)carbonyl)
amino)-4-(tert-butoxy)-4-oxobutanoic acid (29.1 g, 106.4mmol) in
DCM (600mL) were added N,O-dimethylhydroxylamine hydro-
chloride (12.4 g, 127.8mmol), 4-methylmorpholine (14.05mL,
127.8mmol) and 1,(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride (24.5 g, 127.8mmol). After 3 h of stirring at room
temperature, the medium was washed with aqueous HCl (0.2 N),
with water, with brine, dried over sodium sulphate, filtered and
concentrated in vacuo to afford tert-butyl (S)-3-(((allyloxy)
carbonyl)amino)-4-(methoxy(methyl)amino)-4-oxo-butanoate
(29.2 g, 86%) as a yellow oil: LCMS ESIþ m/z 317.3 (MþH)þ; 1H NMR
(CDCl3, 500MHz) d 5.85e5.93 (m, 1H), 5.59 (br d, J¼ 8.5 Hz, 1H),
5.30 (m, 1H), 5.19 (m, 1H), 5.00 (m, 1H), 4.56 (m, 2H), 3.78 (s, 3H),
3.21 (s, 3H), 2.70 (dd, J¼ 15.0 Hz and 5.5 Hz, 1H), 2.54 (dd,
J¼ 15.0 Hz and 6.5 Hz, 1H), 1.43 (s, 9H).
Step 3: A solution of lithium aluminium hydride (2 N in THF,
5.93mL, 11.8mmol) was added dropwise to a cooled (78 C) so-
lution of tert-butyl (S)-3-(((allyloxy)carbonyl)amino)-4-(methox-
y(methyl)amino)-4-oxobutanoate (5.0 g, 15.8mmol) in anhydrous
THF (65mL). The mixture was stirred at 78 C for 2 h, then
aqueous HCl (1 N) was slowly added to the medium and the tem-
perature was allowed to warm to 0 C. The mixture was diluted
with EtOAc. The aqueous layer was extracted (EtOAc, two times).
The combined organic layer was washed with aqueous HCl (0.5 N),
with brine, dried over sodium sulphate, filtered and concentrated
in vacuo to afford tert-butyl (S)-3-(((allyloxy)carbonyl)amino)-4-
oxobutanoate (3.4 g, 83%) as a pale pink oil: 1H NMR (CDCl3)
d 9.66 (s, 1H), 5.83 (br d, 1H), 5.99e5.82 (m, 1H), 5.33 (m, 1H), 5.24
(m, 1H), 4.61 (m, 2H), 4.36 (m, 1H), 2.96 (dd, J¼ 17.2 Hz and 4.5 Hz,
1H), 2.76 (dd, J¼ 17.2 Hz and 5.1 Hz, 1H), 1.43 (s, 9H).
Step 4: To a freshly prepared solution of tert-butyl (S)-3-(((ally-
loxy)carbonyl)amino)-4-oxobutanoate (3.40 g, 13.23mmol) in ab-
solute ethanol (11mL) were added, under Argon atmosphere,
triethyl orthoformate (5.62mL, 33.09mmol), p-toluenesulfonic
acid (45mg, 0.26mmol) and 3Å molecular sieves. After stirring at
room temperature overnight, the mixture was filtered over a pad of
Celite and rinsed with EtOH. The filtrate was concentrated under
reduced pressure and co-evaporated with toluene (three times).
Purification of the residue by flash chromatography on silica gel
(cyclohexane-EtOAc 9/1 to 8/2) afforded the title compound (6,
4.05 g, 92%) as a colorless oil): 1H NMR (CDCl3) d 5.83e6.00 (m,1H),
5.30 (d, J¼ 17.4 Hz, 1H), 5.23 (br d, J¼ 8.5 Hz, 1H), 5.21 (m, 1H), 4.56
(m, 2H), 4.49 (m, 1H), 4.22e4.11 (m, 1H), 3.78e3.65 (m, 2H),
3.61e3.48 (m, 2H), 2.56 (dd, J¼ 15.6 Hz and 5.7 Hz, 1H), 2.45 (dd,
J¼ 15.6 Hz and 7.2 Hz, 1H), 1.44 (s, 9H), 1.21 (m, 6H); 13C NMR
(101MHz, DMSO‑d6) d 170.12, 155.44, 133.78, 116.66, 102.57, 79.66,
64.16, 63.39, 62.22, 50.44, 36.09, 27.69, 15.15; [a]D20¼18.3
(c ¼ 16 g/L, MeCN); HRMS: (MþH)þ calculated for C16H29NO6
331.1995; found 354.1886 (MþNa)þ, 685.3883 (2MþNa)þ, 230.1022
cyclized warhead eg., (M(-OEt,-tBu)þ H)þ.
4.1.6. N-((3R)-1-((2S)-1-(((3S)-2-Ethoxy-5-oxotetrahydro-furan-3-
yl)amino)-1-oxopropan-2-yl)-2,5-dioxopyrrolidin-3-yl)-2-
naphthamide (7)
To a degassed solution (argon sparging, 5min) of N-Alloc pro-
tected warhead 6 (803mg, 2.42mmol) and dimethylbarbituric acid
(315mg, 2.02mmol) in DCM (15mL) at room temperature was
added Pd(PPh3)4 (42mg, 36 mmol, 0.015 eq). The solution was
stirred at room temperature for 15min (TLC (cyclohexane/EtOAc, 7/
3) showed deprotection was complete). At the same time, the acid
derivative obtained above (687mg, 2.02mmol) in solution in a
mixture DCM/DMF (8 mL/7mL) at 0 C was treated with EDCI
(580mg, 3.03mmol) and HOBt (273mg, 2.02mmol). The reaction
mixture was stirred for 5min. Then, the solution of the amine
prepared above was added dropwise. The reaction mixture was
stirred at room temperature for 16 h. After removal of solvents, the
residue was taken-up in EtOAc and aq. saturated NH4Cl. After
separation, aqueous phase was extracted with EtOAc. The com-
bined organics were washed sequentially with aq. sat. NaHCO3, 1N
HCl and brine, then dried over Na2SO4, filtered and concentrated
under vacuum. The residue was purified by silica gel flash chro-
matography (cyclohexane/EtOAc, gradient of 1/0 to 1/4). The ex-
pected product was isolated as a beige solid (830mg, 72%): Rf¼ 0.3
(cyclohexane/EtOAc 2/3); LCMS (tR¼ 3.67min, purity¼ 100%) ESIþ
m/z 570 (MþH)þ; 1H NMR (500MHz, CDCl3) d 8.31 (s, 1H),
7.84e7.72 (m, 5H), 7.54e7.46 (m, 2H), 7.16 (d, J¼ 8.5 Hz,1H), 4.92 (q,
J¼ 7.3 Hz, 1H), 4.68 (m, 1H), 4.60e4.52 (m, 2H), 3.83e3.70 (m, 2H),
3.65e3.55 (m, 2H), 3.24 (dd, J¼ 18.5, 9.5 Hz, 1H), 2.99 (dd, J¼ 18.5,
5.5 Hz, 1H), 2.70e2.55 (m, 2H), 1.71 (d, J¼ 7.0 Hz, 3H), 1.39 (s, 9H),
1.24 (t, J¼ 7.0 Hz, 3H), 1.23 (t, J¼ 7.0 Hz, 3H).
4.1.7. N-((3R)-1-((2S)-1-(((3S)-2-Ethoxy-5-oxotetrahydro-furan-3-
yl)amino)-1-oxopropan-2-yl)-2,5-dioxopyrrolidin-3-yl)-2-
naphthamide (8)
To a solution of N-((3R)-1-((2S)-1-(((3S)-2-ethoxy-5-
oxotetrahydrofuran-3-yl)amino)-1-oxopropan-2-yl)-2,5-dioxo-
pyrrolidin-3-yl)-2-naphthamide (830mg, 1.46mmol) in DCM
(15mL) at 0 C was added TFA (1.12mL, 14.6mmol, 10 eq). The
mixture was stirred for 45min at 0 C, then the solvent and excess
TFAwere removed. The residue was co-evaporated with DCM, then
purified by flash chromatography (40 g silica column, cyclohexane/
AcOEt, gradient of 1/0 to 0/1) and then on preparative TLC (cyclo-
hexane/AcOEt 1/4) to give the desired product as a white solid
(405mg, 59%): LCMS (tR¼ 3.18min, purity¼ 93%) ESIþ m/z 468.1
(MþH)þ; 1H NMR (CDCl3, 500MHz) d 8.38 (s,1H), 7.90 (d, J¼ 8.0 Hz,
1H) 7.85 (d, J¼ 7.0 Hz, 1H), 7.80e7.65 (m, 4H), 7.60e7.40 (m, 2H),
5.50 (s, 1H), 4.95 (q, J¼ 7.3 Hz, 1H), 4.44 (t, J¼ 6.7 Hz, 1H), 4.29 (m,
1H), 3.85 (m, 1H), 3.66 (m, 1H), 3.18 (dd, J¼ 18.5, 9.5 Hz, 1H), 3.02
(dd, J¼ 18.5, 5.0 Hz, 1H), 2.91 (dd, J¼ 18.0, 8.0 Hz, 1H), 2.60 (dd,
J¼ 18.0, 2.0 Hz, 1H), 1.63 (d, J¼ 7.0 Hz, 3H), 1.22 (t, J¼ 7.2 Hz, 3H).
4.1.8. N-((3R)-1-((2S)-1-(((3S)-2-Hydroxy-5-oxotetrahydro-furan-
3-yl)amino)-1-oxopropan-2-yl)-2,5-dioxopyrrolidin-3-yl)-2-
naphthamide (1)
To a solution of N-((3R)-1-((2S)-1-(((3S)-2-ethoxy-5-
oxotetrahydrofuran-3-yl)amino)-1-oxopropan-2-yl)-2,5-dioxo-
pyrrolidin-3-yl)-2-naphthamide (330mg, 0.706mmol) in MeCN
(3.5mL) at 0 C was added aq. 2N HCl (3.5mL, 7.1mmol, 10 eq). The
reaction mixture was stirred at room temperature for 4 h, then
extracted with EtOAc. The organic phase was then dried over
Na2SO4, filtered and concentrated under vacuum. The residue was
purified by preparative HPLC (eluent MeCN/H2O/HCO2H). The pure
fractions were frozen and lyophilised to yield expected product
(100mg, 32%) as a white solid: LCMS (tR¼ 3.97min, purity¼ 100%)
ESIþ m/z 440 (MþH)þ; 1H NMR (500MHz, MeOD) d 8.45 (s, 1H),
8.03e7.90 (m, 4H), 7.63e7.55 (m, 2H), 4.83 (overlap with HDO
signal, 1H), 4.65 (dd, J¼ 10.0, 4.0 Hz, 1H), 4.63 (m, 1H), 4.36 (m, 1H),
3.18 (dd, J¼ 18.0, 9.5 Hz, 1H), 2.89 & 2.86 (2 t, J¼ 4.8 Hz, 1H), 2.67 &
2.64 (2 dd, J¼ 6.0, 4.0 Hz, 1H), 2.59e2.51 (m, 1H), 1.60 & 1.61 (2 d,
J¼ 7.5 Hz, 3H); 13C NMR (DMSO‑d6) d 175.43, 174.80, 168.71, 166.81,
134.49, 132.13, 129.01, 128.20, 128.19, 128.10, 127.73, 127.01, 123.80,
102.69, 52.93, 49.20, 48.13, 35.24, 32.79, 13.57; HRMS: (MþH)þ
calculated for C22H21N3O7 440.1379; found 440.14505.
4.2. N-((3R)-1-((2S)-1-(((3S)-2-hydroxy-5-oxotetrahydrofuran-3-
yl)amino)-1-oxopropan-2-yl)-2,6-dioxopiperidin-3-yl)-2-
naphthamide (2) was prepared in 7 steps
4.2.1. tert-Butyl (S)-2-((R)-3-(((benzyloxy)carbonyl)amino)-2,6-
dioxopiperidin-1-yl)propanoate
K2CO3 (55.3mg, 0.400mmol) was added to a solution of (R)-3-
N-Cbz-amino-2,6-dioxo-piperidine (9, 100mg, 0.381mmol) and
tert-butyl (R)-2-(((trifluoromethyl)-sulfonyl)oxy)propanoate
(117mg, 0.419mmol) in anhydrous MeCN (2.0mL) at 0 C. The re-
action mixture was allowed to stir at r.t. for 30 h. The mixture was
diluted with EtOAc, washed with 1N HCl (aq) and the organic phase
was dried over Na2SO4 and concentrated under reduce pressure.
The residue was purified by preparative TLC (cyclohexane/EtOAc, 1/
1) to give the title compound as yellow oil (79mg, 53%): LCMS
(tR¼ 3.47min, purity¼ 100% (ESLD) m/z (ESIþ) 408.2 (MþNH4þ)þ,
391.1 (MþH)þ, 335.1 (M-C4H9); 1H NMR (CDCl3, 500MHz)
d 7.28e7.40 (m, 5H), 5.70 (br s,1H), 5.09e5.24 (m,1H, superposition
with benzylic CH2), 5.13 (s, 2H), 4.24e4.40 (m, 1H), 2.62e2.93 (m,
2H), 2.44e2.59 (m, 1H), 1.74e1.92 (m, 1H), 1.43 (m, 3H, super-
position avec t-Bu), 1.40 (s, 9H); Chiral HPLC (Chiralpak AD, n-
heptane/2-propanol (80/20), 1mL/min. tR¼ 9.91 (minor) & 14.27
(major), ratio 2/98, e.e.¼ 96%.
4.2.2. (S)-2-((R)-3-(((Benzyloxy)carbonyl)amino)-2,6-dioxo-
piperidin-1-yl)propanoic acid (10)
Under argon, to a solution of tert-butyl (S)-2-((R)-3-(((benzy-
loxy)carbonyl)amino)-2,6-dioxopiperidin-1-yl)propan-oate
(412mg, 1.06mmol) in DCM (10mL) at 0 C was added TFA
(2.44mL, 31.66mmol). The reaction mixture was stirred at room
temperature for 4 h. TLC monitoring (cyclohexane/EtOAc, 1/1)
showed complete conversion. The reaction mixture was concen-
trated in vacuum. The residuewas co-evaporated with DCM 4 times
to remove residual TFA. The residue was takeneup in EtOAc and
precipitated in pentane. The off-white solid was filtered, rinsed
with pentane and then evaporated to dryness to give expected
product (416mg, quant) that was usedwithout further purification:
LCMS (tR¼ 2.79min, purity¼ 100%) ESIm/z 333.1 (M-H)-; 1H NMR
(300MHz, DMSO‑d6) d 12.54 (br s, 1H), 7.70 (d, J¼ 8.7 Hz, 1H),
7.28e7.42 (m, 5H), 5.07 (s, 2H), 5.02e5.14 (m, 1H), 4.35e4.55 (m,
1H), 2.82e3.00 (m, 1H), 2.60e2.77 (m, 1H), 1.90e2.02 (m, 2H), 1.29
(d, J¼ 6.9 Hz, 3H).
4.2.3. tert-Butyl (S)-3-((S)-2-((R)-3-(((benzyloxy)carbonyl)-
amino)-2,6-dioxopiperidin-1-yl)propanamido)-4,4-
diethoxybutanoate (11)
To a degassed solution (argon bubbling, 5min) of Warhead 6
(419mg, 1.27mmol, 1.2 eq.) and dimethylbarbituric acid (132mg,
0.845mmol, 0.8 eq.) in DCM (10mL) at room temperature was
added Pd(PPh3)4 (12mg, 10.6 mmol, 0.01 eq.). The solution was
stirred at room temperature for 10min (TLC monitoring (cyclo-
hexane/EtOAc, 7/3) showed deprotection was complete). The acid
derivative (353mg, 1.06mmol) in solution in a mixture DCM/DMF
(5 mL/1mL) was then added followed by HOBt (143mg,1.06mmol)
and EDCI (243mg, 1.27mmol). The reaction mixture was stirred at
room temperature for 20 h. After removal of solvents, the residue
was taken-up in EtOAc and aq. saturated NH4Cl. After separation,
aqueous phase was extracted with EtOAc. The combined organics
were washed sequentially with aq. sat. NaHCO3, 1N HCl, and brine,
then dried over Na2SO4, filtered and concentrated under vacuum.
The residue was purified by silica gel flash chromatography
(cyclohexane/EtOAc, gradient from 1/0 to 1/4). Expected product
was isolated as a white solid (371mg, 62%): LCMS (tR¼ 3.75min,
purity¼ 90%) ESIþ m/z 564.4 (MþH)þ; 1H NMR (300MHz, CDCl3)
d 7.30e7.40 (m, 5H), 6.73 & 6.58 (2d, J¼ 8.6 Hz, 1H), 5.70 (br s, 1H),
5.15e5.28 (m, 1H), 5.13 (s, 2H), 4.25e4.50 (m, 3H), 3.60e3.80 (m,
2H), 3.48e3.60 (m, 2H), 2.67e2.95 (m, 2H), 2.37e2.58 (m, 3H),
1.90e2.07 (m, 1H), 1.50 (d, J¼ 6.9 Hz, 3H), 1.41 (s, 9H), 1.13e1.23 (m,
6H).
4.2.4. tert-Butyl (S)-3-((S)-2-((R)-3-amino-2,6-dioxopiperidin-1-
yl)propanamido)-4,4-diethoxybutanoate
To a degassed solution of tert-butyl (S)-3-((S)-2-((R)-3-(((ben-
zyloxy)carbonyl)amino)-2,6-dioxopiperidin-1-yl)propan-amido)-
4,4-diethoxybutanoate (371mg, 0.658mmol) in EtOH (20mL) 20%
Pd(OH)2/C (100mg) was added. The reaction mixture was hydro-
genated under 1 atm of H2 at room temperature for 6 h. The reac-
tion mixture was then filled with argon. TLC monitoring of the
reaction (cyclohexane/EtOAc, 3/7) showed a complete conversion.
The medium was filtered on Celite and rinsed with EtOH. After
evaporation to dryness, the brown solid obtained (290mg, quant.)
was used without further purification in the next step: LCMS
(tR¼ 2.56min, purity¼ 90%), ESIþ m/z 430.3 (MþH)þ; 1H NMR
(300MHz, CDCl3) d 6.68 (d, J¼ 8.5 Hz, 1H), 5.16e5.28 (m, 1H),
4.46e4.54 (m, 1H), 4.27e4.38 (m, 1H), 3.42e3.80 (m, 5H),
2.80e2.93 (m, 1H), 2.60e2.77 (m, 1H), 2.38e2.56 (m, 2H), 1.19 (t,
J¼ 7.0 Hz, 6H), 1.43 (s, 9H), 1.50 (br d, 3H), 1.64e1.77 (m, 2H),
1.80e1.98 (m, 1H), 2.16e2.28 (m, 1H).
4.2.5. tert-Butyl (S)-3-((S)-2-((R)-3-(2-naphthamido)-2,6-
dioxopiperidin-1-yl)propanamido)-4,4-diethoxybutanoate (12)
To a solution of the tert-butyl (S)-3-((S)-2-((R)-3-(((benzyloxy)
carbonyl)amino)-2,6-dioxopiperidin-1-yl)propan-amido)-4,4-
diethoxybutanoate obtained above (283mg, 0.659mmol) in THF
(5mL) cooled to 0 C, were successively added DIPEA (0.207mL,
1.19mmol) and 2-naphthoyl chloride (163mg, 0.856mmol). The
reaction mixture was stirred at room temperature for 4 h. LCMS
monitoring showed disappearance of starting material. The reac-
tion mixture was then directly concentrated under reduced pres-
sure with silica. The residue was purified by silica gel flash
chromatography (cyclohexane/EtOAc, gradient of 9/1 to 3/7) to give
the expected product (318mg, 83%) as a pink solid: LCMS
(tR¼ 3.15min, purity¼ 99%) ESIþ m/z 584.2 (MþH)þ; 1H NMR
(300MHz, DMSO‑d6) d 9.01 & 9.13 (2d, J¼ 8.5 Hz, 1H), 8.50 (s, 1H),
7.92e8.10 (m, 4H), 7.58e7.68 (m, 2H), 7.48 & 7.57 (2d, J¼ 8.4 Hz,
1H), 4.92e5.12 (m, 1.5H), 4.80e4.92 (m, 0.2H), 4.42 (d, J¼ 5.1 Hz,
1H), 4.36e4.26 (m, 0.3H), 4.25e4.12 (m, 1H), 3.68e3.39 (m, 4H),
2.54e2.95 (m, 2H), 2.00e2.50 (m, 4H), 1.30e1.41 (s and m, 9H and
3H), 1.04e1.13 (m, 6H).
4.2.6. N-((3R)-1-((2S)-1-(((3S)-2-ethoxy-5-oxotetrahydrofuran-3-
yl)amino)-1-oxopropan-2-yl)-2,6-dioxopiperidin-3-yl)-2-
naphthamide
To tert-butyl (S)-3-((S)-2-((R)-3-(2-naphthamido)-2,6-dioxo-
piperidin-1-yl)propanamido)-4,4-diethoxybutanoate (12, 314mg,
0.534mmol) suspended in DCM (4mL) at 0 C was added TFA
(414.5 mL, 5.38mmol). After 1 h of stirring at 0 C, the solvent and
excess TFA were evaporated. The residue was taken-up in EtOAc
and washed with aq. sat NaHCO3 solution. The aqueous phase was
extracted 5 times with EtOAc. The combined organics were dried
over Na2SO4, filtered and concentrated under vacuum. The residue
was purified by flash chromatography on silica gel (cyclohexane/
EtOA, gradient of 1/1 to 0/1) to yield expected product (195mg,
75%) as a white solid: LCMS (tR¼ 3.10min, purity¼ 93%) ESIþ m/z
482.2 (MþH)þ; 1H NMR (300MHz, DMSO‑d6) d 9.02e9.14 (m, 1H).
8.50 (s, 1H), 8.09e8.15 (m, 0.6H) 7.90e8.09 (m, 4H), 7.56e7.69 (m,
2H), 5.53 (d, J¼ 5.1 Hz, 0.3H), 5.30e5.35 (m, 0.5H), 4.80e5.12 (m,
1.7H), 4.50e4.65 (m, 0.3H), 4.05e4.15 (m, 1H), 3.52e3.80 (m, 2H),
2.54e3.06 (m, 3H), 2.00e2.50 (m, 3H), 1.24e1.39 (m, 3H), 1.10e1.20
(m, 3H).
4.2.7. N-((3R)-1-((2S)-1-(((3S)-2-hydroxy-5-oxotetrahydro-furan-
3-yl)amino)-1-oxopropan-2-yl)-2,6-dioxopiperidin-3-yl)-2-
naphthamide (2)
To a suspension of N-((3R)-1-((2S)-1-(((3S)-2-ethoxy-5-
oxotetrahydrofuran-3-yl)amino)-1-oxopropan-2-yl)-2,6-dioxo-
piperidin-3-yl)-2-naphthamide (190mg, 394.6 mmol) in acetoni-
trile (2.5mL) was added aq. 2N HCl (1.97mL, 3.95mmol, 10 eq.).
After 6 h of stirring at room temperature, LCMSmonitoring showed
complete conversion. The reaction mixturewas diluted with EtOAc.
The phases were separated and the aqueous phase was extracted
with EtOAc (5 6mL). The combined organics were then dried
over Na2SO4, filtered and concentrated under reduced pressure.
The residue (173mg) was purified by preparative HPLC (MeCN/
H2O/HCO2H 10mM). The pure fractions were frozen and lyophi-
lised to yield expected product 2 (93mg, 52%) as a white solid:
LCMS (tR¼ 4.06min, purity¼ 97%) ESIþ m/z 454.5 (MþH)þ: 1H
NMR (300MHz, DMSO‑d6) d 8.95e9.15 (m, 1H), 8.51 (s, 1H),
7.93e8.10 (m, 4H), 7.72 (m, 1H), 7.56e7.68 (m, 2H), 5.50 (m, 1H),
4.76e5.15 (m, 2H), 3.95e4.25 (m, 1H), 2.67e3.02 (m, 3H),
2.38e2.50 (m, 1H), 2.15e2.37 (m, 1H), 2.20e2.50 (m, 1H), 1.95e2.10
(m, 1H), 1.31 & 1.36 (2 d, J¼ 6.9 Hz, 3H).
4.3. N-(3-(1-(((3S)-2-Hydroxy-5-oxotetrahydrofuran-3-yl)
carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)
benzamide (16) was prepared in 12 steps
4.3.1. 1-Ureidocyclopropane-1-carboxylic acid (18)
A suspension of 1-aminocyclopropane-1-carboxylic acid (17,
120 g, 1.19mol, 1.0 eq.) and potassium cyanate (150 g, 1.85mol, 1.56
eq.) inwater (500mL) was heated to reflux temperature during 3 h.
Upon completion the mixture was cooled to 3 C and aqueous hy-
drochloric acid 37% (200mL, 2.03 eq.) was slowly added (CARE:
vigorous CO2 gas release) to adjust to pH 2 and a white precipitate
appeared. The white precipitate was filtered, washed with iced
water (250mL) acetone (3 255mL) and dried. 1-
Ureidocyclopropane-1-carboxylic acid (18, 133.7 g, 78%) was ob-
tained as a white solid: LCMS (tR¼ 0.22min, purity¼ 100%) ESIþm/
z 144.94 (MþH)þ, 166.99 (MþNa)þ; 1H NMR (400MHz, DMSO‑d6)
d 6.61 (s, 1H), 5.55 (s, 2H), 1.26 (q, J¼ 4.2 Hz, 2H), 0.93 (q, J¼ 4.2 Hz,
2H); 13C NMR (101MHz, DMSO‑d6) d 173.80, 158.71, 51.96, 17.47.
4.3.2. Allyl 1-ureidocyclopropane-1-carboxylate (19)
To a suspension of 1-ureidocyclopropane-1-carboxylic acid (18,
122 g, 0.85mol, 1 eq.) in a tetrahydrofuran (1 L)/water (100mL)
mixture was added N,N-diisopropylethylamine (175mL, 1.02mol,
1.2 eq.) and allyl bromide (88mL, 1.02mol, 1.2 eq.). The reaction
mixturewas heated to reflux during 18 h. Upon completionmixture
was cooled to room temperature then saturated aqueous ammo-
nium chloride solution (300mL) and ethyl acetate (1 L) were added.
The aqueous phasewas extractedwith ethyl acetate (2 1 L) and 2-
methyltetrahydrofuran (5 1 L). The organic phases were gathered
and concentrated under reduced pressure to 1.5L liter. The organic
phase was washed with saturated aqueous ammonium chloride
solution (2 100mL), dried over MgSO4, filtered, and concentrated
under reduced pressure. The white solid obtained was triturated in
diisopropyl ether (1.25 L), filtered, washed with diisopropyl ether
and dried. Allyl 1-ureidocyclopropane-1-carboxylate (19, 67.8 g,
68%) was obtained as a white solid: LCMS (tR¼ 0.50min, pu-
rity¼ 90%) ESIþ m/z 184.98 (MþH)þ; 1H NMR (400MHz, DMSO‑d6)
d 6.66 (s, 1H), 5.88 (ddt, J¼ 17.3, 10.3, 5.0 Hz, 1H), 5.58 (s, 2H),
5.39e5.11 (m, 2H), 4.53 (dt, J¼ 5.0, 1.7 Hz, 2H), 1.33 (q, J¼ 4.3 Hz,
2H), 1.02 (q, J¼ 4.4 Hz, 2H); 13C NMR (101MHz, DMSO‑d6) d 172.97,
158.73, 132.65, 117.10, 64.66, 33.49, 17.51; HRMS: (MþH)þ calcu-
lated for C8H12N2O3 185.0848; found 185.0921.
4.3.3. Allyl (E/Z) 1-(3-(3-ethoxy-2-nitro-3-oxoprop-1-en-1-yl)
ureido)cyclopropane-1-carboxylate (20)
To a suspension of allyl 1-ureidocyclopropane-1-carboxylate
(19, 95.0 g, 0.52mol, 1 eq.) in toluene (500mL) were successively
added ethyl nitroacetate (69mL, 0.62mol, 1.2 eq) and triethyl
orthoformate (103mL, 0.62mol, 1.2 eq.). The reaction mixture was
heated to reflux during 15 h. To complete the reaction 2 further
additions of ethyl nitroacetate (2 12mL, 2 0.2 eq) and triethyl
orthoformate (2 17mL, 2 0.2 eq.) were added. Upon reaction
completion heptane (1 L) was slowly added at reflux temperature.
The heating was stopped and the reaction mixture slowly crystal-
lised. The yellow solid was filtered, washed with heptane and dried.
Allyl 1-(3-(3-ethoxy-2-nitro-3-oxoprop-1-en-1-yl)ureido)-cyclo-
propane-1-carboxylate (20, 135 g, 79%) was obtained as a yellow
solid as ~7/3 mixture of E/Z isomers: LCMS (tR¼ 1.04min, pu-
rity¼ 100%) ESIþ m/z 328.00 (MþH)þ; 1H NMR (400MHz,
DMSO‑d6) d 10.81 (d, J¼ 13.2 Hz, 0.7 H), 10.29 (d, J¼ 12.7 Hz, 0.3 H),
8.93 (s, 0.3H), 8.87 (d, J¼ 12.7 Hz, 0.3H), 8.76 (s, 0.7H), 8.50 (d,
J¼ 13.3 Hz, 0.7H), 5.89 (m, 1H), 5.28 (dq, J¼ 17.2, 1.7 Hz, 1H), 5.21
(dq, J¼ 10.5, 1.5 Hz, 1H), 4.62e4.50 (m, 2H), 4.33 (q, J¼ 7.1 Hz,
0.8 H), 4.23 (q, J¼ 7.1 Hz,1.2 H),1.48 (q, J¼ 4.7 Hz, 2H), 1.37e1.16 (m,
5H); 13C NMR (101MHz, DMSO‑d6) d 171.24, 159.93, 152.08, 141.43,
132.42, 119.58, 117.53, 65.24, 61.21, 33.60, 17.11, 14.07; HRMS:
(MþH)þ calculated for C13H17N3O7 328.1066; found 328.1137.
4.3.4. Allyl 1-(5-nitro-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)
cyclopropane-1-carboxylate (21)
A suspension of allyl 1-(3-(3-ethoxy-2-nitro-3-oxoprop-1-en-1-
yl)ureido)cyclopropane-1-carboxylate (20, 135 g, 0.41mol, 1 eq.)
and cesium carbonate (296 g, 0.91mol, 2.2 eq.) in acetonitrile
(1.35 L) was heated under reflux for 30min. The reaction mixture
was cooled to room temperature and diisopropyl ether (500mL)
was added. The organic phase was discarded and the basic aqueous
phase was cooled to 5 C and pH was adjusted to 2 with aqueous
hydrochloric acid 37% [CARE: Vigorous release of CO2(g)]. The acidic
aqueous phase was extracted with dichloromethane (2 1 L) and
the organic phase was dried over magnesium sulphate and evapo-
rated under reduce pressure. A brown oil was obtained and
precipitated in an isopropanol/diisopropyl ether mixture. The solid
was filtered, washed with diisopropyl ether (500mL) and dried.
Allyl 1-(5-nitro-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)cyclopro-
pane-1-carboxylate (21, 83.1 g, 73%) was obtained as an orange
solid: LCMS (tR¼ 0.83min, purity¼ 100%) ESIþ m/z 280.07 (M-H)-;
1H NMR (400MHz, DMSO‑d6) d 12.65 (s, 1H), 8.97 (s, 1H), 5.85 (m,
1H), 5.28e5.13 (m, 2H), 4.58 (m, 2H),1.83e1.72 (m, 2H),1.41 (m, 2H).
4.3.5. Allyl 1-(3-isopropyl-5-nitro-2,6-dioxo-3,6-dihydro-
pyrimidin-1(2H)-yl)cyclopropane-1-carboxylate (22)
To a stirred suspension of 1-(5-nitro-2,6-dioxo-3,6-dihydro-2H-
pyrimidin-1-yl)-cyclopropanecarboxylic acid allyl ester (21, 4.58 g,
16.3mmol, 1.00 eq.) and K2CO3 (3.38 g, 0.02mol, 1.50 eq.) in DMF
(91.6mL) at r.t., was added 2-iodopropane (8.15mL, 81.5mmol, 5.00
eq.) and the suspension was stirred at r.t. for 24 h. The reaction
mixturewas slowly added towater and the product was extracted in
EtOAc (3 100mL). The organic phases were combined, washed
with water (3 50mL), dried over MgSO4 and concentrated to dry-
ness. The residue was purified by flash chromatography (silica gel,
gradient 0e20% EtOAc in heptane) to afford 1-(3-isopropyl-5-nitro-
2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl)-cyclopropanecarboxylic
acid allyl ester (22, 2.41 g, 46%) as awhite solid: LCMS (tR¼ 1.04min,
purity¼ 99%), ESIþm/z 324.5 (MþH)þ; 1HNMR (400MHz, DMSO‑d6)
d 9.13 (s, 1H), 5.97e5.69 (m, 1H), 5.31e5.05 (m, 2H), 4.79e4.68 (m,
1H), 4.58 (ddt, J¼ 8.5, 4.9,1.7 Hz, 2H),1.91e1.59 (m,2H),1.50e1.10 (m,
8H).
4.3.6. Allyl 1-(5-amino-3-isopropyl-2,6-dioxo-3,6-dihydro-
pyrimidin-1(2H)-yl)cyclopropane-1-carboxylate (23)
A stirred suspension of 1-(3-isopropyl-5-nitro-2,6-dioxo-3,6-
dihydro-2H-pyrimidin-1-yl)-cyclopropanecarboxylic acid allyl ester
(22, 2.41 g, 7.45mmol, 1.00 eq.), ammonium chloride (0.20 g,
3.73mmol, 0.50 eq.), iron (1.67 g, 29.8mmol, 4.00 eq.) in amixture of
EtOH (14.5mL), THF (14.5mL) and water (14.5mL) was heated at
70 C for 1 h. The reactionmixturewas cooled to r.t., filtered through
a pad of Celite and washed with EtOH (5 5mL). The filtrate was
concentrated to dryness to afford 1-(5-amino-3-isopropyl-2,6-
dioxo-3,6-dihydro-2H-pyrimidin-1-yl)-cyclopropanecarboxylic acid
allyl ester (23, 2.31 g, 98%) as an orange gum: LCMS (tR¼ 0.99min,
purity¼ 100%), ESIþ m/z 294.16 (MþH)þ; 1H NMR (400MHz,
DMSO‑d6) d 6.96 (s, 1H), 5.92e5.75 (m, 1H), 5.28e5.08 (m, 2H),
4.79e4.63 (m,1H), 4.61e4.42 (m, 2H), 4.09 (s, 2H),1.83e1.61 (m, 2H),
1.41e1.30 (m, 2H), 1.25e1.15 (m, 6H); 13C NMR (101MHz, DMSO‑d6)
d 170.51, 160.39, 149.39, 132.32, 122.42, 116.63, 115.19, 64.86, 47.04,
39.05, 35.46, 20.92, 20.48,19.53,19.33; HRMS (MþH)þ calculated for
C14H19N3O4 294.1375; found 294.1448.
4.3.7. 2-Methyl-4-(naphthalen-2-ylamino)benzoic acid (24)
Step 1: A stirred solution of 2-aminonaphthalene (2.38 g,
16.63mmol, 1.00 eq.), 4-bromo-2-methyl-benzoic acid methyl ester
(4.00 g,17.5mmol,1.05 eq.), palladium(II) acetate (373mg,1.66mmol,
0.10 eq.), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (1.92 g,
3.33mmol, 0.20 eq.) and cesium carbonate (7.04 g, 21.6mmol, 1.30
eq.) in 1,4-dioxanne (38.1mL) was degased and purgedwith nitrogen
then heated at 120 C under microwave irradiation for 30min. The
reaction was concentrated to dryness and partitioned between DCM
(50mL) and water (5mL). The organic phase was retained and the
aqueous phasewas washedwith DCM (3 5mL). The organic phases
were combined, washed with water (10mL), dried over MgSO4 and
concentrated to dryness to afford a pale yellow residue. The residue
was triturated with a mixture of DCM and heptane to afford a solid
thatwas collected byfiltration anddried to a constantweight to afford
2-methyl-4-(naphthalen-2-ylamino)-benzoic acid methyl ester
(4.30 g, 89%) as a pale brown solid: LCMS (tR¼ 1.35min, pu-
rity¼ 100%), ESIþm/z 292.01 (MþH)þ; 1H NMR (400MHz, DMSO‑d6)
d 8.89 (s, 1H), 7.93e7.75 (m, 5H), 7.63 (d, J¼ 2.2 Hz, 1H), 7.44 (ddd,
J¼ 8.2, 6.8,1.3Hz,1H), 7.40e7.29 (m, 2H), 7.05 (dd, J¼ 8.6, 2.4 Hz,1H),
7.00 (d, J¼ 2.3Hz, 1H), 3.78 (s, 3H), 2.50 (s, 3H under DMSO signal).
Step 2: To a stirred solution of 2-methyl-4-(naphthalen-2-
ylamino)-benzoic acid methyl ester (4.00 g, 13.7mmol, 1.00 eq.)
in a mixture of THF (80.0mL) and MeOH (20.0mL), was added
lithium hydroxide (1.0M, 41.2mL, 41.2mmol, 3.00 eq.). The reac-
tion mixture was stirred at 50 C overnight, concentrated to a
minimum volume and the residue was partitioned between DCM
(30mL) and water (5mL). The pH of the aqueous phase was
adjusted to 1 by the addition of HCl (aq) (1.0M) resulting in a thick
precipitate that was collected by filtration and dried to a constant
weight to afford 2-methyl-4-(naphthalen-2-ylamino)benzoic acid
(24, 3.50 g, 92%) as a beige solid: LCMS (tR¼ 1.20min, pu-
rity¼ 100%), ESIþ m/z 278.02 (MþH)þ; 1H NMR (400MHz,
DMSO‑d6) d 12.19 (br s, 1H), 8.82 (s, 1H), 7.98e7.72 (m, 4H), 7.61 (d,
J¼ 2.3 Hz, 1H), 7.50e7.25 (m, 3H), 7.10e6.90 (m, 2H), 2.51 (s, 3H
hidden by DMSO signal); 13C NMR (101MHz, DMSO‑d6) d 168.07,
146.95, 141.82, 139.60, 134.19, 132.88, 129.01, 127.51, 128.96, 126.66,
126.43, 123.72, 120.18, 117.95, 112.68, 112.31, 22.25; HRMS: (MþH)þ
calculated for C18H15NO2 278.1102; found 278.1172.
4.3.8. Allyl 1-(3-isopropyl-5-(2-methyl-4-(naphthalen-2-ylamino)
benzamido)-2,6-dioxo-3,6-dihydro-pyrimidin-1(2H)-yl)
cyclopropane-1-carboxylate
To a stirred solution of 2-methyl-4-(naphthalen-2-ylamino)-
benzoic acid (24, 520mg, 1.88mmol, 1.10 eq.) and N-methyl-
morpholine (375 mL, 3.41mmol, 2.00 eq.) in DMF (10.0mL) at r.t.,
was added COMU ({[1-cyano-1-ethoxycarbonyl-meth-(Z)-ylide-
neaminooxy]-morpholin-4-yl-methylene}-dimethyl-ammonium
hexafluorophosphate) (876mg, 2.05mmol, 1.20 eq.) and the reac-
tion mixture was stirred at r.t. for 30min 1-(5-amino-3-isopropyl-
2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl)-cyclo-
propanecarboxylic acid allyl ester (500mg, 1.70mmol, 1.00 eq.) in
DMF (5.00mL) was added and the reaction mixture was heated at
50 C for 48 h. The reaction mixture was treated with a saturated
solution of NaHCO3(aq) and the product extracted with EtOAc
(3 30mL). The organic phases were combined and washed with
water (3 10mL), dried over MgSO4 and concentrated to dryness.
The crude product was purified by flash chromatography (silica gel,
gradient of 0e100% EtOAc in heptane) to afford 1-{3-Isopropyl-5-
[2-methyl-4-(naphthalen-2-ylamino)-benzoylamino]-2,6-dioxo-
3,6-dihydro-2H-pyrimidin-1-yl}-cyclopropanecarboxylic acid allyl
ester (850mg, 90%) as a pale yellow solid: LCMS (tR¼ 1.43min,
purity¼ 100%), ESIþ m/z 533.22 (MþH)þ; 1H NMR (400MHz,
DMSO‑d6) d 8.98 (s, 1H), 8.69 (s, 1H), 8.30 (s, 1H), 7.93e7.68 (m, 4H),
7.57 (d, J¼ 2.2 Hz, 1H), 7.51 (d, J¼ 8.4 Hz, 1H), 7.42 (ddd, J¼ 8.2, 6.8,
1.4 Hz, 1H), 7.37e7.28 (m, 2H), 7.10e6.99 (m, 2H), 5.85 (ddt, J¼ 17.3,
10.7, 4.8 Hz, 1H), 5.33e5.01 (m, 2H), 4.77 (h, J¼ 6.7 Hz, 1H),
4.70e4.43 (m, 2H), 2.43 (s, 3H), 1.84e1.64 (m, 2H), 1.55e1.20 (m,
8H); 13C NMR (DMSO‑d6) d 170.24, 159.94, 149.89, 145.30, 140.18,
138.35, 134.26, 132.27, 131.18, 129.61, 128.98, 128.70, 127.50, 126.50,
126.40, 126.19, 123.44, 120.58, 118.16, 116.88, 113.03, 112.76, 111.48,
65.04, 54.95, 48.38, 35.67, 20.93, 20.58, 19.48, 19.22; HRMS:
(MþH)þ calculated for C32H32N4O5 553.2372; found 553.2443.
4.3.9. 1-(3-Isopropyl-5-(2-methyl-4-(naphthalen-2-ylamino)-
benzamido)-2,6-dioxo-3,6-dihydro-pyrimidin-1(2H)-yl)
cyclopropane-1-carboxylic acid (25)
A stirred solution of 1-{3-isopropyl-5-[2-methyl-4-(naph-
thalen-2-ylamino)-benzoylamino]-2,6-dioxo-3,6-dihydro-2H-pyr-
imidin-1-yl}-cyclopropanecarboxylic acid allyl ester (840mg,
1.52mmol, 1.00 eq.), 1,3-dimethylbarbituric acid (380mg,
2.43mmol, 1.60 eq.) in DCM (42mL) was degassed and purgedwith
nitrogen and tetrakis(triphenylphosphine)palladium(0) (70.3mg,
0.06mmol, 0.04 eq.) was added. The reactionmixture was stirred at
r.t. for 45min, concentrated and purified by flash chromatography
(silica gel, gradient of 0e10% MeOH in DCM) to afford 1-{3-
isopropyl-5-[2-methyl-4-(naphthalen-2-ylamino)-benzoylamino]-
2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl}-cyclopropane-carbox-
ylic acid (25, 470mg, 60%) as a beige solid: LCMS (tR¼ 1.23min,
purity¼ 99%), ESIþ m/z 513.14 (MþH)þ; 1H NMR (400MHz,
DMSO‑d6) d 1H NMR (400MHz, DMSO‑d6) d 12.6 (br s, 1H), 8.93 (s,
1H), 8.69 (s, 1H), 8.28 (s, 1H), 7.92e7.70 (m, 3H), 7.57 (d, J¼ 2.2 Hz,
1H), 7.51 (d, J¼ 8.3 Hz, 1H), 7.42 (ddd, J¼ 8.2, 6.8, 1.3 Hz, 1H),
7.37e7.28 (m, 2H), 7.09e7.00 (m, 2H), 4.96e4.49 (m, 1H), 2.44 (s,
3H), 1.67 (m, 2H), 1.45e1.20 (m, 8H).
4.3.10. Allyl ((3S)-2-ethoxy-5-oxotetrahydrofuran-3-yl)-carbamate
(26)
To a cooled (4 C) solution of tert-butyl (S)-3-(((allyloxy)
carbonyl)amino)-4,4-diethoxybutanoate (6, 5.0 g, 15.1mmol) in
DCM (20mL) was added trifluoroacetic acid (11.6mL, 151mmol).
After 30min of stirring at room temperature, the mixture was
concentrated under vacuum, then co-evaporated with EtOAc. Pu-
rification of the residue by flash chromatography on silica gel
(cyclohexane-EtOAc, gradient of 95/5 to 6/4) afforded the title
compound (2.45 g, 71%) as a pink oil as a 1:1.2 mixture of two di-
astereoisomers): LCMS ESIþ m/z 229.9 (MþH)þ; 1H NMR (CDCl3,
500MHz) d 5.97e5.85 (m, 1H), 5.44 (d, J¼ 5.0 Hz, 0.5 H), 5.40 (br s,
0.5 H), 5.36e5.22 (m, 2.5H), 5.00 (br s, 0.5 H), 4.62e4.57 (m, 2H),
4.57e4.52 (br s, 0.5H), 4.20 (br t, J¼ 6.5 Hz, 0.5H), 3.95e3.83 (m,
1H), 3.69e3.62 (m, 1H), 3.01 (dd, J¼ 18.0 Hz and 7.5 Hz, 0.5H), 2.84
(dd, J¼ 17.0 Hz and 8.5 Hz, 0.5H), 2.46 (dd, J¼ 17.0 Hz and 10.5 Hz,
0.5H), 2.39 (dd, J¼ 18.0 Hz and 1.4 Hz, 0.5H),1.26 (t, J¼ 7.0 Hz,1.5H),
1.24 (t, J¼ 7.0 Hz, 1.5H); 13C NMR (101MHz, DMSO‑d6) d 174.71,
173.78, 155.73, 155.56, 133.58, 117.00, 107.23, 102.14, 65.16, 64.60,
52.85, 49.47, 32.89, 31.30, 14.90; HRMS: (MþH)þ calculated for
C10H15NO5 229.0950; found 230.1023.
4.3.11. N-(3-(1-(((3S)-2-Ethoxy-5-oxotetrahydrofuran-3-yl)-
carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)
benzamide (27)
First Step: To a stirred solution of 1-{3-isopropyl-5-[2-methyl-4-
(naphthalen-2-ylamino)-benzoylamino]-2,6-dioxo-3,6-dihydro-2H-
pyrimidin-1-yl}-cyclopropanecarboxylic acid, (1.39 g, 2.71mmol,1.00
eq.) and N-methyl morpholine (358 mL, 3.25mmol, 1.20 eq.) in a
mixture of DCM (13.90mL) and DMF (13.90mL), HATU (1.24 g,
3.25mmol,1.20eq.)wasaddedandthe reactionmixturewas stirredat
r.t. for 40min.
Second Step: In parallel, a solution of ((S)-2-ethoxy-5-oxo-tetra-
hydro-furan-3-yl)-carbamic acid allyl ester, (870mg, 3.80mmol,
1.40 eq.) et 1,3-dimethylbarbituric acid (593mg, 3.80mmol,1.40 eq.)
in amixtureofDCM(9.73mL) andDMF(6.95mL) at r.t.wasdegassed
and purged with nitrogen then tetrakis(triphenylphosphine)palla-
dium(0) (125mg; 0.11mmol; 0.04 eq.) was added. The reaction
mixture was stirred at room temperature for 1 h.
Third step: The product, (4S)-4-amino-5-ethoxydihydrofuran-
2(3H)-one, from the Alloc deprotection step was added to the pre-
activated ester for the first step and the reaction mixture was stir-
redat roomtemperatureovernight. The reactionmixturewas treated
with a saturated solution of NaHCO3(aq) and the product extracted
with EtOAc (2 50mL). The organic phases were combined and
washedwith water (3 10mL), dried over MgSO4 and concentrated
to dryness. The crude product was purified by flash chromatography
(silica gel, gradient of 0e5% MeOH in DCM) to afford N-{3-[1-((S)-2-
ethoxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-cyclopropyl]-1-
isopropyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl}-2-methyl-
4-(naphthalen-2-ylamino)-benzamide (1.80 g, quant.) as an orange
solid (mixture of diastereoisomers): LCMS (tR¼ 1.27min, pu-
rity¼ 99%), ESIþ m/z 640.30 (MþH)þ; 1H NMR (400MHz, DMSO‑d6)
d 8.93e8.77 (m, 1H), 8.71 (s, 1H), 8.43 (s, 1H), 7.88e7.72 (m, 3H),
7.67e7.53 (m, 2H), 7.49 (t, J¼ 8.3 Hz,1H), 7.43 (ddd, J¼ 8.1, 6.8,1.2 Hz,
1H), 7.36e7.27 (m, 2H), 7.12e6.98 (m, 2H), 5.50 (m, 0.5H), 5.22 (m,
0.5H), 4.60e4.70 (m, 0.5H), 4.10e4.20 (m, 0.5H), 3.70e3.80 (m, 1H),
3.55e3.65 (m,1H), 2.80e3.20 (m, 0.5H), 2.72e2.56 (m,1.5H), 2.44 (s,
3H), 1.60e1.70 (m, 2H), 1.40e1.26 (m, 6H), 1.10e1.20 (m, 5H); 13C
NMR (101MHz, DMSO‑d6) d 174.01, 170.12, 169.94, 160.04, 167.21,
149.85, 145.42, 140.12, 138.30, 134.26, 129.47, 128.99, 128.73, 127.51,
126.51, 126.41, 123.48, 120.60, 118.21, 113.97, 112.84, 111.56, 102.12,
65.49, 48.10, 37.30, 37.22, 26.89, 21.04, 20.82, 20.57, 19.31; HRMS:
(MþH)þ calculated for C35H37N5O7 640.2693; found 640.27563.
4.3.12. N-(3-(1-(((3S)-2-Hydroxy-5-oxotetrahydrofuran-3-yl)
carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)
benzamide (16)
To a stirred solution of N-{3-[1-((S)-2-ethoxy-5-oxo-tetrahydro-
furan-3-ylcarbamoyl)-cyclopropyl]-1-isopropyl-2,4-dioxo-1,2,3,4-
tetrahydro-pyrimidin-5-yl}-2-methyl-4-(naphthalen-2-ylamino)-
benzamide (1.72 g, 2.69mmol, 1.00 eq.) in MeCN (34.4mL) was
added HCl (aq) (2M, 13.4mL, 26.9mmol, 10.0 eq.) and the reaction
mixturewas stirred at room temperature for 5 h. The volatiles were
eliminated under a flow of nitrogen and the residue was treated
with a saturated aqueous solution of NaHCO3 (pH 8) then diluted
with EtOAc. The organic phase was discarded and the pH of the
aqueous phase was adjusted to 5 with AcOH. The product was
extracted in EtOAc (3 20mL), the organic phases were combined,
dried over MgSO4 and concentrated to dryness. The resulting beige
solid was crystallised from amixture of EtOAc/toluene and the solid
was recuperated by filtration and dried to a constant weight un a
vacuum oven at 40 C to afford N-(3-(1-(((3S)-2-hydroxy-5-
oxotetrahydrofuran-3-yl)carbamoyl)cyclopropyl)-1-isopropyl-2,4-
dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methyl-4-(naph-
thalen-2-ylamino)benzamide (1.07 g, 65%) as an off-white solid:
LCMS (tR¼ 6.47min, purity¼ 99%), ESI m/z 610.62 (MþH)þ; 1H
NMR (400MHz, DMSO‑d6) d 8.96e8.83 (m, 1H), 8.71 (s, 1H), 8.42 (s,
1H), 8.21 (s br, 1H), 7.87e7.73 (m, 3H), 7.58 (d, J¼ 2.3 Hz, 1H), 7.50
(d, J¼ 8.4 Hz, 1H), 7.43 (ddd, J¼ 8.2, 6.8, 1.3 Hz, 1H), 7.36e7.27 (m,
2H), 7.07 (dd, J¼ 8.3, 2.3 Hz, 1H), 7.03 (d, J¼ 2.3 Hz, 1H), 5.41 (s br,
1H), 4.78 (m, 1H), 4.15 (s br, 1H), 2.93 (m, 1H), 2.44 (s, 3H), 2.32 (m,
1H), 1.65 (m, 2H), 1.32 (dd, J¼ 13.1, 6.7 Hz, 6H), 1.16 (m, 2H); 13C
NMR (400MHz, DMSO‑d6) d 167.31, 160.22, 149.87, 145.41, 140.15,
138.33, 134.28, 129.53, 129.02, 128.75, 128.48, 127.53, 126.53,
126.44, 126.14, 123.50, 120.61, 118.24, 113.99, 112.86, 111.55, 48.09,
39.07, 37.32, 20.98, 20.84, 20.60, 19.38; HRMS: (MþH)þ calculated
for C33H33N5O7 612.2380; found 612.2376; analytical chiral HPLC
conditions (Chiralpak IC 4.6 mm*250 mm 5 mm column; eluent, n-
heptane/EtOH/TEA (80/20/0.5); flow rate, 1.0mL/min.; run time,
50min; tR¼ 12.287min (S enantiomer), tR¼ 20.100min (R enan-
tiomer), e.r.¼ 95:5 (S/R).
4.4. Checking the hydrolysis step for epimerization
4.4.1. (S)-4-Hydroxy-3-(1-(3-isopropyl-5-(2-methyl-4-
(naphthalen-2-ylamino)benzamido)-2,6-dioxo-3,6-dihydro-
pyrimidin-1(2H)-yl)cyclopropane-1-carboxamido)butanoic acid
(29)
To a stirred solution of N-(3-(1-(((3S)-2-hydroxy-5-
oxotetrahydrofuran-3-yl)carbamoyl)cyclopropyl)-1-isopropyl-2,4-
dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-
2-ylamino)benzamide (16, 85.0mg, 0.14mmol) in MeOH (850 mL)
was added portionwise NaBH4 (10.5mg, 0.28mmol) at 0 C and the
reaction mixture was stirred at r.t. for 3 h 30min. The reaction
mixture was concentrated to dryness and the residue partitioned
between EtOAc (50mL) and water (5mL). The organic phase was
washed with water (1 5mL), dried over MgSO4 and concentrated
to dryness. The residue was purified by mass-triggered preparative
LCMS to afford (S)-4-hydroxy-3-(1-(3-isopropyl-5-(2-methyl-4-
(naphthalen-2-ylamino)benzamido)-2,6-dioxo-3,6-dihydropyri-
midin-1(2H)-yl)cyclopropane-1-carbox-amido)butanoic acid (29,
53.0mg, 60%) as a cream coloured solid: LCMS (tR¼ 1.15min, pu-
rity¼ 98%, MS ES m/z 612.55 (M-H)-; 1H NMR (400MHz,
DMSO‑d6) d 8.83 (s, 1H), 8.71 (s, 1H), 8.40 (s, 1H), 7.92e7.67 (m, 3H),
7.58 (d, J¼ 2.1 Hz, 1H), 7.50e7.59 (m, 2H), 7.43 (ddd, J¼ 8.2, 6.8,
1.3 Hz, 1H), 7.37e7.28 (m, 2H), 7.10e7.01 (m, 2H), 4.76 (h, J¼ 6.9 Hz,
1H), 4.04 (m, 1H), 3.30e3.40 (m, 1H), 3.28e3.07 (m, 1H), 2.44 (s,
3H), 2.38e2.21 (m, 1H), 1.75e1.52 (m, 2H), 1.32 (m, 6H), 1.11 (s, 2H);
13C NMR (101MHz, DMSO‑d6) d 172.78, 169.06, 167.23, 160.13,
149.86, 145.39,140.14, 134.26,138.31, 129.48, 129.00, 128.73, 128.33,
127.51, 126.52, 126.41, 126.11, 123.47, 120.60, 118.23, 113.91, 112.85,
111.53, 62.51, 59.80, 48.79, 48.06, 37.48, 20.59, 18.82, 14.14; HRMS:
(MþH)þ calculated for C33H35N5O7 614.2536; found 614.2606;
[a]D20¼10.0 (c¼ 2.5 g/L, ACN); analytical chiral HPLC conditions
(Chiralpak ID 4.6 mm*250 mm 5 mm column; eluent, n-heptane/
EtOH/AcOH (80/20/0.1); flow rate, 1.5mL/min.; run time, 50min;
tR¼ 23.959min (S enantiomer), tR¼ 30.891min (R enantiomer),
e.r.¼ 95:5 (S/R).
4.4.2. (S,E)-4-((benzyloxy)imino)-3-(1-(3-isopropyl-5-(2-methyl-
4-(naphthalen-2-ylamino)benzamido)-2,6-dioxo-3,6-dihydro-
pyrimidin-1(2H)-yl)cyclopropane-1-carboxamido)butanoic acid
(30)
To a stirred solution of N-{3-[1-((S)-2-hydroxy-5-oxo-tetrahy-
dro-furan-3-ylcarbamoyl)-cyclopropyl]-1-isopropyl-2,4-dioxo-
1,2,3,4-tetrahydro-pyrimidin-5-yl}-2-methyl-4-(naphthalen-2-
ylamino)-benzamide (16, 103mg, 0.17mmol, 1.00 eq.) and pyridine
(27.2 mL, 0.34mmol, 2.00 eq.) in a mixture of THF (2.58mL) and
MeOH (2.58mL), was added O-benzylhydroxylamine (52.3 mL,
0.51mmol, 3.00 eq.) and the reaction mixture was heated at 80 C
for 1 h. The resulting solution was cooled to r.t. and partitioned
between EtOAc (20mL) and a saturated aqueous solution of NH4Cl
(5mL). The organic phase was retained and the aqueous phase was
washed with EtOAc (3 5mL). The organic phases were combined,
dried over MgSO4 and concentrated to dryness and the residue was
purified by flash chromatography (silica gel, gradient of 0e5%
MeOH in DCM) to afford (S,E)-4-((benzyloxy)imino)-3-(1-(3-
isopropyl-5-(2-methyl-4-(naphthalen-2-ylamino)benzamido)-2,6-
dioxo-3,6-dihydro-pyrimidin-1(2H)-yl)cyclopropane-1-
carboxamido)-butanoic acid (30, 103mg, 83%) as a cream coloured
solid: LCMS (tR¼ 1.30min, purity¼ 100%), ESI m/z 715.28 (M-H)-;
1H NMR (400MHz, DMSO‑d6) 1H NMR (400MHz, DMSO‑d6) d 12.35
(br s, 1H), 8.99e8.84 (m, 1H), 8.76 (s, 1H), 8.46 (d, J¼ 2.5 Hz, 1H),
8.22 (s,1H), 8.04e7.75 (m, 3H), 7.63 (d, J¼ 2.5 Hz,1H), 7.59e7.43 (m,
2H), 7.42e7.29 (m, 5H), 7.20e6.94 (m, 2H), 6.77 (d, J¼ 5.8 Hz, 1H),
5.13 (s, 0.5H), 5.04 (s, 1.5H), 4.93e4.67 (m, 1H), 4.05 (m, 1H),
2.81e2.62 (m, 2H), 2.49 (s, 3H), 1.68 (m, 2H), 1.37 (m, 6H), 1.26e1.11
(m, 2H); 13C NMR (DMSO‑d6) d 171.50,169.25,167.24,149.74,145.38,
140.14, 138.32, 137.31, 134.26, 129.49, 128.99, 128.72, 128.41, 128.33,
127.86, 127.61, 127.51, 126.51, 126.41, 126.12, 123.47, 118.23, 120.59,
113.96, 112.84, 111.52, 75.24, 47.99, 46.01, 45.76, 40.13, 37.36, 20.99,
20.77, 20.58; HRMS (MþH)þ calculated for C40H40N6O7 717.29585;
found 717.30273; [a]D20¼10.0 (c¼ 2.5 g/L, ACN); analytical chiral
HPLC conditions (Chiralpak ID 4.6 mm*250mml 5 mm column;
eluent, n-heptane/EtOH/AcOH (80/20/0.1); flow rate, 1.5mL/min.;
run time, 50min; tR¼ 27.857min (S enantiomer), tR¼ 35.022min
(R enantiomer), e.r.¼ 93:7 (S/R).
4.5. N-(3-(1-(((3S)-2-Hydroxy-3-methyl-5-oxotetrahydro-furan-3-
yl)amino)-1-oxopropan-2-yl)-1-methyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-4-(quinoxalin-2-ylamino)benzamide
(36) was prepared in 6 steps
4.5.1. (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-(tert-
butoxy)-2-methyl-4-oxo-butanoic acid (32)
To a stirred solution of 10% w/v Na2CO3 (4.17 g, 39.4mmol, 4.00
eq.), was added dropwise a solution of (S)-2-amino-2-methyl-suc-
cinic acid 4-tert-butyl ester (31, 2.00 g, 9.84mmol, 1.00 eq.) in 1,4-
dioxanne (50mL). After 10min, a solution of Fmoc-OSu (3.98 g,
11.81mmol, 1.20 eq.) in 1,4-dioxanne (40mL) was added to the re-
action mixture and the resulting suspension was stirred at r.t.
overnight. The reactionmixture was diluted with water (20mL) and
the pH adjusted to 6 with 1N HCl (aq). The product was extracted
with EtOAc (3 50mL) and the organic phases were combined and
washedwith water (3 20mL), dried overMgSO4 and concentrated
to dryness to afford the crude product. The crude product was pu-
rified by flash chromatography (silica gel, gradient 0e10% MeOH in
DCM) to afford (S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-2-
methyl-succinic acid 4-tert-butyl ester (32, 3.54 g, 85%) as a white
solid: LCMS (tR¼ 1.22min, purity¼ 99%), MS ES m/z 424 (M-H)-;
1H NMR (400MHz, DMSO‑d6) d 12.8 (br s,1H), 7.90 (d, J¼ 7.4 Hz,1H),
7.71 (dd, J¼ 7.7, 2.6 Hz, 1H), 7.42 (td, J¼ 7.5, 1.1 Hz, 1H), 7.33 (t,
J¼ 7.5 Hz,1H), 4.34e4.13 (m, 3H), 2.87 (d, J¼ 14.3 Hz,1H), 2.76e2.60
(m, 1H), 1.43 (s, 3H), 1.35 (s, 9H).
4.5.2. tert-Butyl (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)-
amino)-4-hydroxy-3-methylbutanoate
To a stirred solution of (S)-2-(9H-fluoren-9-ylmethoxy-
carbonylamino)-2-methyl-succinic acid 4-tert-butyl ester (32,
2.00 g, 4.72mmol, 1.00 eq.), N-methylmorpholine (1.03mL,
9.44mmol, 2.00 eq.) in DCM (40mL) at 0 C, was added isobutyl
chloroformate (1.22mL, 9.44mol, 2.00 eq.) and the solution was
stirred at 0 C for 1 h. Solid sodium borohydride (534mg, 14.2mol,
3.00 eq.) was added and the reaction mixture was stirred at 0 C for
1 h and at r.t. overnight. The reaction mixture was washed with
water (3 5mL), dried over MgSO4 and concentrated to dryness to
afford (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(tert-
butoxy)-2-methyl-4-oxo-butanoic acid (1.90 g, 98%) as a white
solid: LCMS (tR¼ 1.25min, purity¼ 99%), MS ESIþ m/z 434
(MþNa)þ; 1H NMR (400MHz, DMSO‑d6) d 7.95e7.84 (m, 1H), 7.73
(d, J¼ 7.5 Hz, 1H), 7.42 (td, J¼ 7.5, 1.2 Hz, 1H), 7.33 (tt, J¼ 7.5, 1.1 Hz,
1H), 6.84 (br s, 1H), 4.79 (s, 1H), 4.21 (d, J¼ 4.6 Hz, 2H), 3.76 (m, 2H),
2.90e2.68 (m, 1H), 2.51 (m, 1H), 1.36 (s, 9H), 1.23 (s, 3H).
4.5.3. tert-Butyl (S)-3-amino-4-hydroxy-3-methylbutanoate (33)
To a stirred solution of (S)-3-(9H-fluoren-9-ylmethoxy-
carbonylamino)-4-hydroxy-3-methyl-butyric acid tert-butyl ester
(1.50 g, 3.65mmol, 1.00 eq.) in MeCN (15.0mL) at r.t., was added
pyrrolidine (60.2 mL, 0.73mmol, 0.20 eq.). The reaction mixture was
stirred at r.t. for 24 h and concentrated to dryness. The residue was
suspended in toluene and concentrated to dryness to afford tert-
butyl (S)-3-amino-4-hydroxy-3-methylbutanoate (690mg, quant.)
as a pale yellow gum that was used without further purification:
LCMS (tR¼ 1.25min, purity¼ 99%), ESIþ m/z 134 (M-C4H9þH)þ.
4.5.4. tert-Butyl (3S)-4-hydroxy-3-methyl-3-(2-(3-methyl-2,6-
dioxo-5-(4-(quinoxalin-2-ylamino)benzamido)-3,6-dihydro-
pyrimidin-1(2H)-yl)propanamido)butanoate (35)
To a stirred solution of 2-{3-methyl-2,6-dioxo-5-[4-(quinoxalin-
2-ylamino)-benzoylamino]-3,6-dihydro-2H-pyrimidin-1-yl}-pro-
pionic acid (34, 120mg, 0.26mmol, 1.00 eq.) and N-methyl-
morpholine (34.4 mL, 0.31mmol, 1.20 eq.) in DMF (2.40mL) at r.t.,
was added HATU (119mg, 0.31mmol, 1.20 eq.) and the reaction
mixture was stirred for 1 h 30 at r.t. then tert-butyl (S)-3-amino-4-
hydroxy-3-methylbutanoate (33, 98.7mg, 0.52mmol, 2.00 eq.) was
added and the reaction mixture was heated at 80 C for 4 h and left
to stir at r.t. for 48 h. The reaction mixture was partitioned between
EtOAc (50mL) and water (5mL). The organic phase was retained
and the aqueous phases washed with EtOAC (3 10mL). The
organic phases were combined, washed with water (4 10mL),
dried over MgSO4 and concentrated to dryness. The residue was
purified by flash chromatography (silica gel, gradient of 0e100%
EtOAc in heptane) to afford tert-butyl (3S)-4-hydroxy-3-methyl-3-
(2-(3-methyl-2,6-dioxo-5-(4-(quinoxalin-2-ylamino)benzamido)-
3,6-dihydropyrimidin-1(2H)-yl)propanamido)butanoate (35,
100mg, 45%) as a yellow solid as a mixture of diastereoisomers:
LCMS (tR¼ 1.19min, purity¼ 74%), ESIþ m/z 576.2 (M-C4H9þH)þ,
632.4 (MþH)þ; 1H NMR (400MHz, DMSO‑d6) d 10.29 (s,1H), 9.15 (d,
J¼ 6.3 Hz, 1H), 8.63 (s, 1H), 8.35 (d, J¼ 10.3 Hz, 1H), 8.13 (d,
J¼ 8.7 Hz, 2H), 8.02e7.94 (m, 3H), 7.91 (dd, J¼ 8.1, 1.5 Hz, 1H), 7.82
(dd, J¼ 8.4, 1.3 Hz, 1H), 7.71 (ddd, J¼ 8.4, 6.9, 1.5 Hz, 1H), 7.54 (ddd,
J¼ 8.3, 6.9, 1.4 Hz, 1H), 6.99 (d, J¼ 21.4 Hz, 1H), 5.28 (m, 1H), 4.72 (t,
J¼ 6.1 Hz, 0.5H), 4.59 (t, J¼ 6.1 Hz, 0.5H), 3.52 (m, 2H), 3.42e3.34
(d, J¼ 1.9 Hz, 3H), 2.67e2.55 (m, 1H), 2.46e2.23 (m, 1H), 1.46
(overlapping d, 3H), 1.40 (s, 9H), 1.26 (s, 3H).
4.5.5. tert-Butyl (3S)-4-hydroxy-3-methyl-3-(2-(3-methyl-2,6-
dioxo-5-(4-(quinoxalin-2-ylamino)benzamido)-3,6-dihydro-
pyrimidin-1(2H)-yl)propanamido)butanoate
To a stirred solution of tert-butyl (3S)-4-hydroxy-3-methyl-3-
(2-(3-methyl-2,6-dioxo-5-(4-(quinoxalin-2-ylamino)benzamido)-
3,6-dihydropyrimidin-1(2H)-yl)propanamido)butanoate (35,
100mg, 0.11mmol, 1.00 eq.) in DCM (1.40mL) at 0 C, was added
Dess-Martin periodinane (1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-
benziodoxol-3-(1H)-one) (56.4mg, 0.13mmol, 1.20 eq.) and the
reaction mixture was stirred overnight at r.t. The reaction mixture
was diluted with DCM (20mL), washed with 10% w/v NaHSO4 (aq),
dried over MgSO4 and concentrated to dryness to afford tert-butyl
(3S)-4-hydroxy-3-methyl-3-(2-(3-methyl-2,6-dioxo-5-(4-(quinox-
alin-2-ylamino)benzamido)-3,6-dihydropyrimidin-1(2H)-yl)prop-
anamido)butanoate (100mg, quant.) as a complex mixture of
diastereisomers: LCMS (tR¼ 1.22min, purity¼ 96%), MS ESIþ m/z
630.4 (MþH)þ; 1H NMR (400MHz, DMSO‑d6) d 10.30 (s, 1H), 9.28
(d, J¼ 16.0 Hz, 1H), 9.13 (d, J¼ 27.6 Hz, 1H), 8.63 (s, 1H), 8.36 (d,
J¼ 3.9 Hz, 1H), 8.26 (d, J¼ 5.5 Hz, 1H), 8.18e7.95 (m, 3H), 7.94e7.85
(m, 4H), 7.85e7.76 (m, 4H), 7.71 (ddd, J¼ 8.4, 7.0, 1.6 Hz, 2H),
7.60e7.47 (m, 2H), 5.31 (m, 1H), 3.40 (d, J¼ 3.5 Hz, 3H), 2.81e2.59
(m, 2H), 1.47 (overlapping d, 3H),1.40 (overlapping s, 9H),1.28e1.22
(overlapping s, 3H).
4.5.6. N-(3-(1-(((3S)-2-Hydroxy-3-methyl-5-oxotetrahydro-furan-
3-yl)amino)-1-oxopropan-2-yl)-1-methyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-4-(quinoxalin-2-ylamino)benzamide
(36)
To a stirred solution of tert-butyl (3S)-4-hydroxy-3-methyl-3-
(2-(3-methyl-2,6-dioxo-5-(4-(quinoxalin-2-ylamino)benzamido)-
3,6-dihydropyrimidin-1(2H)-yl)propanamido)butanoate (100mg,
0.11mmol, 1.00 eq.) in DCM (700 mL) at r.t., was added TFA (60 mL,
0.78mmol, 7.00 eq.) and the reaction mixture is stirred at r.t. for
1 h. The reaction mixture was concentrated and the residue was
purified by flash chromatography (silica gel, gradient of 0e5%
MeOH in DCM) to afford N-(3-(1-(((3S)-2-Hydroxy-3-methyl-5-
oxotetrahydrofuran-3-yl)amino)-1-oxopropan-2-yl)-1-methyl-
2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4-(quinoxalin-2-
ylamino)benzamide (35, 25.0 mg, 36%) as a beige solid: LCMS
(tR¼ 0.97min, purity¼ 96%), ESIþ m/z 574.23 (MþH)þ; 1H NMR
(400MHz, DMSO‑d6) d 10.36 (s, 1H), 9.16 (s, 1H), 8.64 (s, 1H), 8.34
(d, J¼ 9.4 Hz, 1H), 8.14 (d, J¼ 8.6 Hz, 2H), 7.99 (d, J¼ 8.6 Hz, 2H),
7.92 (d, J¼ 8.0 Hz,1H), 7.82 (d, J¼ 8.0 Hz,1H), 7.71 (t, J¼ 7.7 Hz,1H),
7.54 (t, J¼ 7.7 Hz, 1H), 5.28 (br m, 1H), 3.38 (d, J¼ 3.7 Hz, 3H),
2.52e2.49 (hidden m, 2H), 1.45 (br s, 3H), 1.31 (br s, 3H).
4.6. N-(3-(1-(((3R)-2-hydroxy-5-oxotetrahydrofuran-3-yl)-
carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)
benzamide (28) was prepared in 6 steps
4.6.1. (R)-2-(((Allyloxy)carbonyl)amino)-4-(tert-butoxy)-4-oxo-
butanoic acid
To a cooled (4 C) solution of D-aspartic acid 4-tert-butyl ester
(15.0 g, 78.3mmol) in THF/H2O (50mL/150mL) were added sodium
bicarbonate (26.6 g, 317.1mmol) and allyl chloroformate (15.17mL,
57 g, 142.7mmol). After 3h of stirring at room temperature, the
mediumwas extracted with EtOAc (three times). The aqueous layer
was acidified with aqueous HCl (6 N) until obtaining pH 2. The
aqueous layer was extracted (EtOAc, three times). The combined
organic layer was dried over sodium sulphate, filtered and
concentrated in vacuo to afford the title compound (18.7 g, 87%, as
colorless oil): LCMS ESI m/z 272.4 (M-H)-; 1H NMR (CDCl3,
500MHz) d 5.96e5.87 (m, 1H), 5.74 (br d, J¼ 8.5 Hz, 1H), 5.31 (m,
1H), 5.22 (m, 1H), 4.65e4.55 (m, 3H), 2.97 (dd, J¼ 17.0 Hz and
4.0 Hz, 1H), 2.76 (dd, J¼ 17.0 Hz and 5.0 Hz, 1H), 1.44 (s, 9H).
4.6.2. tert-Butyl (R)-3-(((allyloxy)carbonyl)amino)-4-
(methoxy(methyl)amino)-4-oxo-butanoate
To a cooled solution of (R)-2-(((allyloxy)carbonyl)amino)-4-
(tert-butoxy)-4-oxobutanoic acid (18.7 g, 68.7mmol) in DCM
(390mL) were added N,O-dimethylhydroxylamine hydrochloride
(8.00 g, 82.4mmol), 4-methylmorpholine (9.07mL, 82.4mmol) and
1,(3-dimethylaminopropyl)-3-ethylcarbodiimide hydro-chloride
(15.8 g, 82.4mmol). After 3 h of stirring at room temperature, the
mediumwaswashedwith aqueous HCl (1 N, two times), with brine,
dried over sodium sulphate, filtered and concentrated in vacuo.
Purification of the residue by chromatography on silica gel (cyclo-
hexane-EtOAc, gradient of 9/1 to 7/3) afforded the title compound
(15.3 g, 71%, as yellow oil): LCMS ESIþ m/z 317.3 (MþH)þ; 1H NMR
(CDCl3, 500MHz) d 5.93e5.85 (m, 1H), 5.59 (br d, J¼ 8.5 Hz, 1H),
5.30 (m, 1H), 5.19 (m, 1H), 5.00 (m, 1H), 4.56 (m, 2H), 3.78 (s, 3H),
3.21 (s, 3H), 2.70 (dd, J¼ 15.0 Hz and 5.5 Hz, 1H), 2.54 (dd,
J¼ 15.0 Hz and 6.5 Hz, 1H), 1.43 (s, 9H).
4.6.3. tert-Butyl (R)-3-(((allyloxy)carbonyl)amino)-4-oxo-
butanoate
A solution of lithium aluminium hydride (2 N in THF, 8.22mL,
16.4mmol) was added dropwise to a cooled (78 C) solution of
tert-butyl (R)-3-(((allyloxy)carbonyl)amino)-4-(methoxy-(methyl)
amino)-4-oxobutanoate (8.0 g, 25.3mmol) in anhydrous THF
(107mL). The mixture was stirred at 78 C for 3 h, then aqueous
HCl (1 N) was slowly added to the medium, and the temperature
was allowed to warm to 0 C. The mixture was diluted with EtOAc.
The aqueous layer was extracted (EtOAc). The combined organic
layer was washed with aqueous HCl (1 N), with brine, dried over
sodium sulphate, filtered and concentrated in vacuo to afford the
title compound (6.65 g, quantitative, as pale yellow oil): 1H NMR
(CDCl3, 500MHz) d 9.66 (s, 1H), 5.83 (br d, 1H), 5.99e5.82 (m, 1H),
5.33 (m, 1H), 5.24 (m, 1H), 4.61 (m, 2H), 4.36 (m, 1H), 2.96 (dd,
J¼ 17.2 Hz and 4.5 Hz, 1H), 2.76 (dd, J¼ 17.2 Hz and 5.1 Hz, 1H), 1.43
(s, 9H).
4.6.4. tert-Butyl (R)-3-(((allyloxy)carbonyl)amino)-4,4-diethoxy-
butanoate
To a freshly prepared solution of tert-butyl (R)-3-(((allyloxy)
carbonyl)amino)-4-oxobutanoate (6.65 g, 25.8mmol) in absolute
ethanol (28mL) were added, under Argon atmosphere, triethyl
orthoformate (12.9mL, 77.5mmol), p-toluenesulfonic acid (133mg,
0.77mmol) and 3Å molecular sieves. After stirring at room tem-
perature for 3 days, the mixture was filtered over a pad of celite and
rinsed with EtOH. The filtrate was concentrated under reduced
pressure. Purification of the residue by flash chromatography on
silica gel (cyclohexane-EtOAc, 9/1) afforded the title compound
(4.87 g, 50%) as colorless oil): 1H NMR (CDCl3, 400MHz)
d 5.83e6.00 (m, 1H), 5.30 (d, J¼ 17.4 Hz, 1H), 5.23 (br d, J¼ 8.5 Hz,
1H), 5.21 (m, 1H), 4.56 (m, 2H), 4.49 (m, 1H), 4.22e4.11 (m, 1H),
3.65e3.78 (m, 2H), 3.48e3.61 (m, 2H), 2.56 (dd, J¼ 15.6 Hz and
5.7 Hz,1H), 2.45 (dd, J¼ 15.6 Hz and 7.2 Hz,1H),1.44 (s, 9H),1.21 (m,
6H); 13C NMR (101MHz, DMSO‑d6) d 170.12, 155.44, 133.78, 116.66,
102.57, 79.66, 64.16, 63.39, 62.22, 50.44, 36.09, 27.69, 15.15;
[a]D20 ¼ þ17.8 (c ¼ 18 g/L, MeCN).
4.6.5. N-(3-(1-(((3R)-2-ethoxy-5-oxotetrahydrofuran-3-yl)
carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)
benzamide
First Step: To a stirred solution of 1-{3-isopropyl-5-[2-methyl-4-
(naphthalen-2-ylamino)-benzoylamino]-2,6-dioxo-3,6-dihydro-
2H-pyrimidin-1-yl}-cyclopropanecarboxylic acid, (283mg,
0.55mmol, 1.00 eq.) and N-methyl morpholine (72.9 mL, 0.66mmol,
1.20 eq.) in a mixture of DCM (1.27mL) and DMF (1.27mL), HATU
(252mg, 0.66mmol, 1.20 eq.) was added and the reaction mixture
was stirred at r.t. for 45min.
Second Step: In parallel, a solution of ((R)-2-ethoxy-5-oxo-tetra-
hydro-furan-3-yl)-carbamic acid allyl ester, (190mg, 0.83mmol,1.40
eq.) and 1,3-dimethylbarbituric acid (129mg, 0.83mmol,1.50 eq.) in
a mixture of DCM (0.89mL) and DMF (0.63mL) at r.t. was degassed
and purged with nitrogen then tetrakis(triphenylphosphine)palla-
dium(0) (25.5mg, 0.02mmol, 0.04 eq.) was added. The reaction
mixture was stirred at room temperature for 1 h.
Third step: The product, (4S)-4-amino-5-ethoxydihydrofuran-
2(3H)-one, from the Alloc deprotection step was added to the pre-
activated ester for the first step and the reaction mixture was stir-
red at room temperature overnight. The reactionmixturewas treated
with a saturated solution of NaHCO3(aq) and the product extracted
with EtOAc (2 20mL). The organic phases were combined and
washedwithwater (3 5mL), driedoverMgSO4 and concentrated to
dryness. The crude product was purified by flash chromatography
(silica gel, gradient of 0e5% MeOH in DCM) to afford N-{3-[1-((R)-2-
ethoxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-cyclopropyl]-1-
isopropyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl}-2-methyl-
4-(naphthalen-2-ylamino)-benzamide (1.80 g, quant.) as an orange
solid (mixture of diastereoisomers): LCMS (tR¼ 1.27min,
purity¼ 100%), ESIþ m/z 640.20 (MþH)þ; 1H NMR (400MHz,
DMSO‑d6) d 8.96e8.75 (overlapping s, 1H), 8.70 (s, 1H), 8.43 (s, 1H),
8.23 (d, J¼ 7.1 Hz, 0.5H), 8.05e7.91 (m, 0.5H), 7.91e7.69 (m, 3H),
7.67e7.53 (m, 3H), 7.52e7.39 (m, 2H), 7.37e7.27 (m, 2H), 7.12e7.00
(m, 2H), 5.50 (d, J¼ 5.3 Hz, 0.5H), 5.22 (d, J¼ 6.0 Hz, 0.5H), 4.90e4.51
(m, 1H), 4.04 (overlapping signals, 0.5H), 3.84e3.47 (overlapping
signals, 2H), 2.99 (m, 0.5H), 2.68e2.53 (m,1H), 2.44 (s, 3H), 2.39e2.28
(m, 1H), 1.83e1.53 (m, 2H), 1.48e1.24 (m, 6H), 1.23e1.06 (m, 5H).
4.6.6. N-(3-(1-(((3R)-2-Hydroxy-5-oxotetrahydrofuran-3-yl)
carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)
benzamide (28)
To a stirred solution of N-{3-[1-((S)-2-ethoxy-5-oxo-tetrahydro-
furan-3-ylcarbamoyl)-cyclopropyl]-1-isopropyl-2,4-dioxo-1,2,3,4-
tetrahydro-pyrimidin-5-yl}-2-methyl-4-(naphthalen-2-ylamino)-
benzamide (280mg, 0.44mmol, 1.00 eq.) in MeCN (5.60mL) was
added HCl (aq) (2M, 2.19mL, 4.38mmol, 10.0 eq.) and the reaction
mixturewas stirred at room temperature for 5 h. The volatiles were
eliminated under a flow of nitrogen and the residue was treated
with a saturated aqueous solution of NaHCO3 (pH 8) then diluted
with EtOAc. The organic phase was discarded and the pH of the
aqueous phase was adjusted to 5 with AcOH. The product was
extracted in EtOAc (3 5mL), the organic phases were combined,
dried over MgSO4 and concentrated to dryness. The resulting beige
solid was crystallised from amixture of EtOAc/toluene and the solid
was recuperated by filtration and dried to a constant weight un a
vacuum oven at 40 C to afford N-(3-(1-(((3R)-2-hydroxy-5-
oxotetrahydrofuran-3-yl)carbamoyl)cyclopropyl)-1-isopropyl-2,4-
dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methyl-4-(naph-
thalen-2-ylamino)benzamide (1.07 g, 65%) as an off-white solid:
LCMS (tR¼ 1.19min, purity¼ 99%), ESIþ m/z 612.36 (MþH)þ; 1H
NMR (400MHz, DMSO‑d6) d 8.96e8.83 (m, 1H), 8.71 (s, 1H), 8.42 (s,
1H), 8.21 (br s, 1H), 7.87e7.73 (m, 3H), 7.58 (d, J¼ 2.3 Hz, 1H), 7.50
(d, J¼ 8.4 Hz, 1H), 7.43 (ddd, J¼ 8.2, 6.8, 1.3 Hz, 1H), 7.36e7.27 (m,
2H), 7.07 (dd, J¼ 8.3, 2.3 Hz, 1H), 7.03 (d, J¼ 2.3 Hz, 1H), 5.41 (br s,
1H), 4.78 (m, 1H), 4.15 (s br, 1H), 2.93 (m, 1H), 2.44 (s, 3H), 2.32 (m,
1H), 1.65 (m, 2H), 1.32 (dd, J¼ 13.1, 6.7 Hz, 6H), 1.16 (m, 2H).
4.7. N-(3-(1-(((4R)-2-hydroxy-6-oxotetrahydro-2H-pyran-4-yl)
carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)-
benzamide (37) was prepared in 7 steps
4.7.1. tert-Butyl (R)-3-((((9H-fluoren-9-yl)methoxy)-carbonyl)-
amino)-5-(methoxy(methyl)amino)-5-oxopentanoate
To a cooled solution of Fmoc-b-homoaspartic acid(O-tBu) (20.0 g,
47.0mmol) inDCM(268mL)wereaddedN,O-dimethylhydroxylamine
hydrochloride (5.5 g, 56.4mmol), 4-methylmorpholine (6.2mL,
56.4mmol) and 1,(3-dimethylaminopropyl)-3-ethylcarbodiimide hy-
drochloride (10.8 g, 56.4mmol). After 2 h of stirring at room temper-
ature, the medium was washed with aqueous HCl (1N, two times),
with brine, dried over sodium sulphate, filtered and concentrated in
vacuo. Purification of the residue by chromatography on silica gel
(cyclohexane-EtOAc, gradient of 8/2 to 6/4) afforded the title com-
pound (22.6 g, quantitative): LCMS (tR¼ 3.75min, purity¼ 100%), ESIþ
m/z469.2 (MþH)þ; 1HNMR(CDCl3) d7.75 (d, J¼ 7.5Hz, 2H), 7.57e7.60
(m, 2H), 7.39 (t, J¼ 7.5Hz, 2H), 7.30 (td, J¼ 7.5Hz and 1.0Hz, 2H), 5.95
(d, J¼ 7.8Hz,1H), 4.40e4.35 (m, 3H), 4.21 (m,1H), 3.70 (s, 3H), 3.21 (s,
3H), 2.97e2.94 (m, 1H), 2.73e2.64 (m, 2H), 2.61 (dd, J¼ 15.7Hz and
7.0Hz, 1H), 1.44 (s, 9H).
4.7.2. tert-Butyl (R)-3-amino-5-(methoxy(methyl)amino)-5-oxo-
pentanoate
To a cooled (0 C) solution of tert-butyl (R)-3-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-5-(methoxy(methyl)amino)-5-
oxopentanoate (22.6 g, 48.2mmol) in DCM (377mL) was added
dropwise DBU (7.92mL, 5.0mmol). After 1 h 30 of stirring at room
temperature, the medium was concentrated under vacuum. Puri-
fication of the residue by chromatography on silica gel (DCM -
MeOH/NH3 (7 N), gradient of 97/3 to 95/5) afforded the title com-
pound (8.11 g, 68%, as yellow oil): 1H NMR (CDCl3) d 3.70e3.63 (m,
1H), 3.68 (s, 3H), 3.17 (s, 3H), 2.64e2.60 (m, 1H), 2.57e2.52 (m, 1H),
2.45 (dd, J¼ 15.8 Hz and 5.0 Hz,1H), 2.39 (dd, J¼ 15.8 Hz and 8.0 Hz,
1H), 1.45 (s, 9H).
4.7.3. tert-Butyl (R)-3-(((allyloxy)carbonyl)amino)-5-(methoxy-
methyl)amino)-5-oxo-pentanoate
To a cooled (4 C) solution of tert-butyl (R)-3-amino-5-
(methoxy(methyl)amino)-5-oxopentanoate (8.11 g, 32.9mmol) in
THF/H2O (20 mL/60mL) were added sodium bicarbonate (41.1 g,
131.6mmol) and allyl chloroformate (6.30mL, 59.2mmol). After 1 h
30 of stirring at room temperature, the mediumwas extracted with
EtOAc (3 20mL). The combined organic layer was dried over so-
dium sulphate, filtered and concentrated in vacuo. Purification of
the residue by chromatography on silica gel (cyclohexane-EtOAc,
gradient of 8/2 to 6/4) afforded the title compound (9.58 g, 88%) as a
colorless oil: 1H NMR (CDCl3) d 5.93e5.83 (m, 2H), 5.29 (d,
J¼ 17.3 Hz, 1H), 5.18 (m, 1H), 4.54 (m, 2H), 4.32e4.36 (m, 1H), 3.67
(s, 3H), 3.17 (s, 3H), 2.91e2.86 (m, 1H), 2.72e2.65 (m, 2H), 2.59 (dd,
J¼ 15.8 Hz and 6.9 Hz, 1H), 1.44 (s, 9H).
4.7.4. tert-Butyl (R)-3-(((allyloxy)carbonyl)amino)-5-oxo-
pentanoate
A solution of lithium aluminium hydride (2 N in THF, 5.90mL,
11.8mmol) was added dropwise to a cooled (78 C) solution of
tert-butyl (R)-3-(((allyloxy)carbonyl)amino)-5-(methoxy-(methyl)
amino)-5-oxopentanoate (6.0 g, 18.1mmol) in anhydrous THF
(80mL). The mixture was stirred at 78 C for 2 h 30, then aqueous
HCl (1 N) was slowly added to the medium, and the temperature
was allowed to warm to 0 C. The mixture was diluted with EtOAc.
The aqueous layer was extracted (EtOAc, two times). The combined
organic layer was washed with aqueous HCl (1 N), with brine, dried
over sodium sulphate, filtered and concentrated in vacuo to afford
the title compound (4.7 g, 95%, as pale yellow oil): 1H NMR (CDCl3)
d 9.75 (t, J¼ 1.4 Hz, 1H), 5.94e5.86 (m, 1H), 5.48 (br s, 1H), 5.29 (m,
1H), 5.20 (m, 1H), 4.54 (d, J¼ 4.9 Hz, 2H), 4.37e4.40 (m, 1H), 2.83
(dd, J¼ 17.5 Hz and 5.5 Hz, 1H), 2.74 (ddd, J¼ 17.5 Hz, 6.0 Hz and
1.4 Hz, 1H), 2.58 (d, J¼ 5.8 Hz, 2H), 1.44 (s, 9H).
4.7.5. tert-Butyl (R)-3-(((allyloxy)carbonyl)amino)-5,5-diethoxy-
pentanoate
To a freshly prepared solution of tert-butyl (R)-3-(((allyloxy)
carbonyl)amino)-5-oxopentanoate (4.7 g, 17.3mmol) in absolute
ethanol (20mL) were added, under Argon atmosphere, triethyl
orthoformate (11.5mL, 69.3mmol), p-toluenesulfonic acid (90mg,
0.52mmol) and 3Å molecular sieves. After stirring at room tem-
perature overnight, themixturewas filtered over a pad of Celite and
rinsed with EtOH. The filtrate was concentrated under reduced
pressure and co-evaporatedwith toluene (three times). Purification
of the residue by flash chromatography on silica gel (cyclohexane-
EtOAc, gradient of 9/1 to 8/2) afforded the title compound (4.85 g,
81%, as pale yellow oil): 1H NMR (400MHz, DMSO‑d6) d 7.13 (d,
J¼ 8.8 Hz, 1H), 5.92e5.85 (m, 1H), 5.27e5.24 (m, 1H), 5.17e5.14 (m,
1H), 4.47e4.44 (m, 3H), 3.90e3.84 (m, 1H), 3.59e3.50 (m, 2H),
3.43e3.73 (m, 2H), 2.36e2.28 (m, 2H), 1.65 (m, 2H),1.37 (s, 9H), 1.09
(m, 6H); 13C NMR (101MHz, DMSO‑d6) d 169.97, 155.13, 133.83,
116.63, 100.06, 79.73, 64.09, 61.11, 60.48, 45.22, 41.12, 38.26, 27.67,
15.29; [a]D20 ¼ þ13.4 (c ¼ 10 g/L, EtOH). HRMS: (MþH)þ calculated
for C17H31NO6 345.2151; found 368.2083 (MþNa)þ, 713.4276
(2MþNa)þ, 244.1206 cyclized warhead eg., (M(-OEt, -C4H9)þH)þ.
4.7.6. tert-Butyl (R)-5,5-Diethoxy-3-(1-(3-isopropyl-5-(2-methyl-
4-(naphthalen-2-ylamino)-benzamido)-2,6-dioxo-3,6-
dihydropyrimidin-1(2H)-yl)cyclopropane-1-carboxamido)-
pentanoate
Step 1: To a stirred solution 1-{3-isopropyl-5-[2-methyl-4-
(naphthalen-2-ylamino)-benzoylamino]-2,6-dioxo-3,6-dihydro-
2H-pyrimidin-1-yl}-cyclopropanecarboxylic acid (100mg,
0.20mmol, 1.00 eq.) and N-methylmorpholine (25.7 mL, 0.23mmol,
1.20 eq.) in a mixture of DCM (700 mL) and DMF (1.00mL), was
added HATU (89.0mg, 0.23mmol, 1.20 eq.) and the reaction
mixture was stirred at room temperature for 30min.
Step 2: In a separate flask, a solution of (R)-3-allyloxy-
carbonylamino-5,5-diethoxy-pentanoic acid tert-butyl ester
(101mg, 0.29mmol, 1.50 eq.) and 1,3-dimethylbarbituric acid
(45.7mg, 0.29mmol, 1.50 eq.) in a mixture of DCM (700 mL) and
DMF (500 mL) was degassed and purged with nitrogen then tetra-
kis(triphenylphosphine)palladium(0) (9.02mg, 0.01mmol, 0.04
eq.) was added. The reaction mixture was stirred at r.t. for 30min.
Step 3: The solution from the Alloc deprotection containing tert-
butyl (R)-3-amino-5,5-diethoxypentanoate was added dropwise to
the activated ester formed in Step 1 and the resulting solution was
stirred for 2 h at r.t. The reaction mixture was diluted with EtOAc
(30mL) and washed with a saturated aqueous solution of NaHCO3.
The aqueous phasewaswashedwith EtOAc (2 10mL). The organic
phases were combined, dried over MgSO4 and concentrated to
dryness. The residue was purified by flash chromatography (silica
gel, gradient of 0e100% EtOAc in heptane) to afford tert-butyl (R)-
5,5-diethoxy-3-(1-(3-isopropyl-5-(2-methyl-4-(naphthalen-2-
ylamino)-benzamido)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)
cyclopropane-1-carboxamido)-pentanoate (140mg, 95%) as a yel-
low solid: LCMS (tR¼ 1.44min, purity¼ 100%), MS ES m/z 754.48
(M-H)-; 1H NMR (400MHz, DMSO‑d6) d 8.83 (d, J¼ 6.3 Hz, 1H), 8.72
(s,1H), 8.42 (d, J¼ 6.3 Hz,1H), 7.89e7.71 (m, 3H), 7.69e7.55 (m, 2H),
7.53e7.38 (m, 2H), 7.38e7.28 (m, 2H), 7.13e6.99 (m, 2H), 4.77 (p,
J¼ 6.7 Hz,1H), 4.46 (dd, J¼ 8.1, 3.1 Hz,1H), 3.49 (overlappingm, 4H),
2.65e2.53 (m,1H), 2.44 (s, 3H), 2.39e2.17 (m,1H),1.81e1.50 (m, 2H),
1.47e1.18 (overlapping signals, 17H), 1.10 (m, 6H).
4.7.7. N-(3-(1-(((4S)-2-hydroxy-6-oxotetrahydro-2H-pyran-4-yl)
carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)-
benzamide (37)
To a stirred solution of (R)-5,5-diethoxy-3-[(1-{3-isopropyl-5-
[2-methyl-4-(naphthalen-2-ylamino)-benzoylamino]-2,6-dioxo-
3,6-dihydro-2H-pyrimidin-1-yl}-cyclopropanecarbonyl)-amino]-
pentanoic acid tert-butyl ester (200mg, 0.26mmol, 1.00 eq.) in
DCM (6.00mL) at 0 C, was added TFA (6.00mL, 78.4mmol)
dropwise over 2min. The reaction mixture was stirred at r.t. for 2 h.
The reaction mixture was carefully added to a mixture of ice and a
saturated solution of NaHCO3 (aq). The pH of the reaction mixture
was brought up to 8 with 1M NaOH (aq) then lowered to 5 with
AcOH and the product extracted with DCM (2 10mL). The organic
extracts were combined, washed with water (2 2mL), dried over
MgSO4 and concentrated to dryness. The residue was purified by
flash chromatography (silica gel, gradient of 2e10% MeOH in DCM)
to afford a yellow solid. The solid was triturated with heptane and
stirred overnight, recuperated by filtration and dried to a constant
weight to afford N-(3-(1-(((4S)-2-hydroxy-6-oxotetrahydro-2H-
pyran-4-yl)carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)-
benzamide (134mg, 80%) as an off-white solid: LCMS
(tR¼ 6.57min, purity¼ 98.4%), ESIþ m/z 626.25 (MþH)þ; 1H NMR
(400MHz, DMSO‑d6) d 9.52 (s, 1H), 8.84 (s, 1H), 8.72 (s, 1H), 8.41 (s,
1H), 7.99 (s, 1H), 7.71e7.88 (m, 3H), 7.58 (d, J¼ 2.4 Hz, 1H), 7.50 (d,
J¼ 8.6 Hz, 1H), 7.43 (ddd, J¼ 8.2, 6.8, 1.3 Hz, 1H), 7.26e7.37 (m, 2H),
6.94e7.03 (m, 2H), 4.76 (s, 1H), 4.46 (s, 1H), 2.30e2.50 (m, 2H), 2.44
(s, 3H), 2.38 (d, J¼ 10.9 Hz, 2H), 1.61 (m, 2H), 1.28e1.38 (m, 6H), 1.11
(s, 2H); 13C NMR (101MHz, DMSO‑d6) d 169.04, 167.23, 160.07,
149.74, 148.66,145.39,140.14,138.32,135.06, 134.26,129.48,128.99,
128.72, 128.33, 127.51, 126.51, 126.40, 126.10, 123.46, 120.60, 118.24,
113.92, 112.85, 111.52, 48.08, 42.61, 37.37, 31.30, 28.41, 22.14, 20.59,
14.00; HRMS (MþH)þ calculated for C34H35N5O7 626.2536; found
626.2605.
4.8. N-(3-(1-(((4S)-2-Hydroxy-6-oxotetrahydro-2H-pyran-4-yl)
carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)
benzamide (38) was prepared in 7 steps
4.8.1. tert-Butyl (S)-3-((((9H-fluoren-9-yl)methoxy)-carbonyl)-
amino)-5-(methoxy(methyl)amino)-5-oxopentanoate
To a cooled solution of (S)-3-((((9H-fluoren-9-yl)methoxy)
carbonyl)amino)-5-(tert-butoxy)-5-oxopentanoic acid (5.0 g,
11.7mmol) in DCM (67mL) were added N,O-dimethylhydroxyl-
amine hydrochloride (1.38 g, 14.1mmol), 4-methylmorpholine
(1.55mL, 14.1mmol) and 1,(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (2.70 g, 14.1mmol). After 2h 30
of stirring at room temperature, the medium was washed with
aqueous HCl (1 N, three times), with saturated aqueous sodium
bicarbonate, with brine, dried over sodium sulphate, filtered and
concentrated in vacuo to afford the title compound (4.98 g, 90%) as
a pale yellow paste: LCMS (tR¼ 3.75min, purity¼ 100%), ESIþ m/z
469.2 (MþH)þ; 1H NMR (CDCl3) d 7.75 (d, J¼ 7.5 Hz, 2H), 7.60e7.57
(m, 2H), 7.39 (t, J¼ 7.5 Hz, 2H), 7.30 (td, J¼ 7.5 Hz and 1.0 Hz, 2H),
5.95 (d, J¼ 7.8 Hz, 1H), 4.40e4.35 (m, 3H), 4.21 (m, 1H), 3.70 (s, 3H),
3.21 (s, 3H), 2.97e2.94 (m, 1H), 2.73e2.68 (m, 2H), 2.61 (dd,
J¼ 15.7 Hz and 7.0 Hz, 1H), 1.44 (s, 9H).
4.8.2. tert-Butyl (S)-3-amino-5-(methoxy(methyl)amino)-5-
oxopentanoate
To a solution of tert-butyl (S)-3-((((9H-fluoren-9-yl)methoxy)
carbonyl)amino)-5-(methoxy(methyl)amino)-5-oxopentanoate
(4.95 g, 10.5mmol) in DCM (80mL) was added dropwise DBU
(1.73mL, 11.6mmol). After 2 h 30 of stirring at room temperature,
the medium was concentrated under vacuum. Purification of the
residue by chromatography on silica gel (DCM - MeOH/NH3 (7 N),
95/5) afforded the title compound (2.45 g, 75%) as a yellow oil; 1H
NMR (CDCl3, 500MHz) d 3.63e3.68 (m, 1H), 3.68 (s, 3H), 3.17 (s,
3H), 2.64e2.60 (m, 1H), 2.57e2.52 (m,1H), 2.45 (dd, J¼ 15.8 Hz and
5.0 Hz, 1H), 2.39 (dd, J¼ 15.8 Hz and 8.0 Hz, 1H), 1.45 (s, 9H).
4.8.3. tert-Butyl (S)-3-(((allyloxy)carbonyl)amino)-5-(methoxy-
(methyl)amino)-5-oxopentanoate
To a cooled (4 C) solution of tert-butyl (S)-3-amino-5-
(methoxy(methyl)amino)-5-oxopentanoate (2.45 g, 9.95mmol) in
THF/H2O (6 mL/18mL) were added sodium bicarbonate (3.34 g,
39.79mmol) and allyl chloroformate (1.90mL, 17.9mmol). After
2h30 of stirring at room temperature, the medium was extracted
with EtOAc (three times). The combined organic layer was dried
over sodium sulphate, filtered and concentrated in vacuo. Purifi-
cation of the residue by chromatography on silica gel (cyclohexane-
EtOAc, gradient of 8/2 to 4/6) afforded the title compound (1.32 g,
40%) as a colorless oil: LCMS (tR¼ 3.00min, purity¼ 100%), ESIþm/
z 331.1 (MþH)þ; 1H NMR (CDCl3) d 5.83e5.93 (m, 2H), 5.29 (d,
J¼ 17.3 Hz, 1H), 5.18 (m, 1H), 4.54 (m, 2H), 4.36e4.32 (m, 1H), 3.67
(s, 3H), 3.17 (s, 3H), 2.91e2.86 (m, 1H), 2.72e2.65 (m, 2H), 2.59 (dd,
J¼ 15.8 Hz and 6.9 Hz, 1H), 1.44 (s, 9H).
4.8.4. tert-Butyl (S)-3-(((allyloxy)carbonyl)amino)-5-oxo-
pentanoate
A solution of lithium aluminium hydride (2 N in THF, 1.28mL,
2.56mmol) was added dropwise to a cooled (78 C) solution of
tert-butyl (S)-3-(((allyloxy)carbonyl)amino)-5-(methoxy-(methyl)
amino)-5-oxopentanoate (1.30 g, 3.93mmol) in anhydrous THF
(16mL). Themixturewas stirred at78 C for 3h, then aqueous HCl
(1 N) was slowly added to the medium, and the temperature was
allowed to warm to 0 C. The mixture was diluted with EtOAc. The
aqueous layer was extracted (EtOAc, two times). The combined
organic layer was washed with aqueous HCl (1 N), with brine, dried
over sodium sulphate, filtered and concentrated in vacuo to afford
the title compound (1.05 g, 98%) as a pale yellow oil: 1H NMR
(CDCl3) d 9.75 (t, J¼ 1.4 Hz, 1H), 5.86e5.94 (m, 1H), 5.48 (br s, 1H),
5.29 (m, 1H), 5.20 (m, 1H), 4.54 (d, J¼ 4.9 Hz, 2H), 4.40e4.37 (m,
1H), 2.83 (dd, J¼ 17.5 Hz and 5.5 Hz, 1H), 2.74 (ddd, J¼ 17.5 Hz,
6.0 Hz and 1.4 Hz, 1H), 2.58 (d, J¼ 5.8 Hz, 2H), 1.44 (s, 9H).
4.8.5. tert-Butyl (S)-3-(((allyloxy)carbonyl)amino)-5,5-diethoxy-
pentanoate
To a freshly prepared solution of tert-butyl (S)-3-(((allyloxy)
carbonyl)amino)-5-oxopentanoate (1.05 g, 3.87mmol) in absolute
ethanol (3.5mL) were added, under an argon atmosphere, triethyl
orthoformate (1.61mL, 9.68mmol), p-toluenesulfonic acid (13mg,
0.077mmol) and 3Å molecular sieves. After stirring at room tem-
perature overnight, the mixturewas filtered over a pad of celite and
rinsed with EtOH. The filtrate was concentrated under reduced
pressure and co-evaporated with toluene (three times). Purification
of the residue by flash chromatography on silica gel (cyclohexane-
EtOAc, gradient of 9/1 to 75/25) afforded the title compound (1.07 g,
80%) as a pale yellow oil; LCMS (tR¼ 3.53min, purity¼ 100%), ESIþ
m/z 300.1 (M(-OEt)þH)þ; 1H NMR (DMSO‑d6, 400MHz) d 7.13 (d,
J¼ 8.8 Hz, 1H), 5.92e5.84 (m, 1H), 5.27e5.24 (m, 1H), 5.17e5.14 (m,
1H), 4.47e4.44 (m, 3H), 3.90e3.84 (m, 1H), 3.59e3.50 (m, 2H),
3.43e3.37 (m, 2H), 2.36e2.28 (m, 2H), 1.65 (m, 2H), 1.37 (s, 9H), 1.09
(m, 6H); 13C NMR (101MHz, DMSO‑d6) d 169.97, 155.13, 133.83,
116.63, 100.06, 79.73, 64.09, 61.11, 60.48, 45.22, 41.12, 38.26, 27.67,
15.29; [a]D20¼12.8 (c ¼ 10 g/L, EtOH); HRMS: (MþH)þ calculated
for C17H31NO6 345.2151; found 368.2082 (MþNa)þ, 713.4275
(2MþNa)þ, 244.1205 cyclized warhead eg., (M(-OEt, -C4H9) þ H)þ.
4.8.6. tert-Butyl (S)-5,5-diethoxy-3-(1-(3-isopropyl-5-(2-methyl-4-
(naphthalen-2-ylamino)-benzamido)-2,6-dioxo-3,6-
dihydropyrimidin-1(2H)-yl)cyclopropane-1-carboxamido)-
pentanoate
Step 1: To a stirred solution of 1-{3-Isopropyl-5-[2-methyl-4-
(naphthalen-2-ylamino)-benzoylamino]-2,6-dioxo-3,6-dihydro-
2H-pyrimidin-1-yl}-cyclopropanecarboxylic acid (100mg,
0.20mmol, 1.00 eq.) and N-methylmorpholine (25.7 mL, 0.23mmol,
1.20 eq.) in a mixture of DCM (700 mL) and DMF (1.00mL), was
added HATU (89.0mg, 0.23mmol, 1.20 eq.) and the reaction
mixture was stirred at room temperature for 30min.
Step2: Inparallel, a stirredsolutionof (S)-3-allyloxycarbonylamino-
5,5-diethoxy-pentanoic acid tert-butyl ester (101mg, 0.29mmol, 1.50
eq.) and 1,3-dimethylbarbituric acid (45.7mg, 0.29mmol,1.50 eq.) in a
mixture of DCM (700 mL) and DMF (500 mL) was degassed and purged
with nitrogen then tetrakis(triphenylphosphine)palladium(0)
(9.02mg, 0.01mmol, 0.04 eq.) was added. The reaction mixture was
agitated for 30min.
Step 3: The solution containing tert-butyl (S)-3-amino-5,5-
diethoxypentanoate was added dropwise to the pre-activated
ester for Step 1 and the resulting solution was stirred for 2 h at r.t.
The reaction mixture was diluted with EtOAc (50mL) and washed
with a saturated aqueous solution of NaHCO3. The aqueous phase
was washed with EtOAc (3 10mL). The organic phases were
combined, dried over MgSO4 and concentrated to dryness. The
residuewas purified by flash chromatography (silica gel, gradient of
0e100% EtOAc in heptane) to afford tert-butyl (S)-5,5-diethoxy-3-
(1-(3-isopropyl-5-(2-methyl-4-(naphthalen-2-ylamino)-benza-
mido)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)cyclopropane-1-
carboxamido)-pentanoate (141mg, 96%) as a beige solid: LCMS
(tR¼ 1.44min, purity¼ 100%), MS ESIm/z 754.63 (M-H)-; 1H NMR
(400MHz, DMSO‑d6) d 8.83 (d, J¼ 6.4 Hz, 1H), 8.72 (s, 1H), 8.42 (d,
J¼ 6.4 Hz, 1H), 7.88e7.72 (m, 3H), 7.69e7.52 (m, 4H), 7.52e7.39 (m,
1H), 7.38e7.27 (m, 2H), 7.12e7.00 (m, 2H), 5.83e5.57 (m, 1H),
5.17e4.95 (m, 1H), 4.90e4.59 (m, 1H), 4.46 (m, 1H), 4.16 (over-
lapping m, 1H), 3.70e3.35 (overlapping m, 4H), 2.75e2.55 (m, 1H),
2.44 (s, 3H), 2.37e2.15 (m, 1H), 1.78e1.53 (m, 2H), 1.46e1.18
(overlapping m, 17H), 1.10 (m, 6H).
4.8.7. N-(3-(1-(((4S)-2-Hydroxy-6-oxotetrahydro-2H-pyran-4-yl)
carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)
benzamide (38)
To a stirred solution of tert-butyl (S)-5,5-diethoxy-3-(1-(3-
isopropyl-5-(2-methyl-4-(naphthalen-2-ylamino)-benzamido)-
2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)cyclopropane-1-
carboxamido)-pentanoate (260mg, 0.34mmol, 1.00 eq.) in DCM
(7.8mL) was added TFA (7.8mL) at 0 C. The reaction mixture is
stirred at r.t. for 2 h. The reaction mixture was carefully added to a
mixture of ice and a saturated solution of NaHCO3 (aq). The pH of
the reaction mixture was lowered to 5 with AcOH and the product
extracted with DCM (2 5mL). The organic extracts were com-
bined, washed with water (2 2mL), dried over MgSO4 and
concentrated to dryness. The residue was purified by flash chro-
matography (silica gel, gradient of 2e10%MeOH in DCM) to afford a
yellow solid. The solid was triturated with heptane and stirred
overnight, recuperated by filtration and dried to a constant weight
to afford N-(3-(1-(((4S)-2-hydroxy-6-oxotetrahydro-2H-pyran-4-
yl)carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2 -ylamino)
benzamide (129mg, 59%) as a pale yellow solid: LCMS
(tR¼ 5.96min, purity¼ 98%), MS ESIþ m/z 624.57 (M-H)-; 1H NMR
(400MHz, DMSO‑d6) d 9.53 (s, 1H), 8.84 (s, 1H), 8.71 (s, 1H), 8.40 (s,
1H), 7.70e7.90 (m, 3H), 7.58 (d, J¼ 2.3 Hz, 1H), 7.50 (d, J¼ 8.5 Hz,
1H), 7.42 (d, J¼ 7.4 Hz, 1H), 7.24e7.38 (m, 2H), 6.94e7.13 (m, 2H),
4.76 (s,1H), 4.42 (s,1H), 2.40e2.50 (m, 2H), 2.44 (s, 3H), 2.32 (s, 2H),
1.69e1.81 (m, 2H), 1.32 (dd, J¼ 11.0, 6.7 Hz, 6H), 1.11 (s, 2H); 13C
NMR (101MHz, DMSO‑d6) d 169.04, 167.23, 160.07, 149.74, 148.66,
145.39,140.14,138.32,135.06,134.26,129.48,128.99,128.72,128.33,
127.51, 126.51, 126.40, 126.10, 123.46, 120.60, 118.24, 113.92, 112.85,
111.52, 48.08, 42.61, 37.37, 31.30, 28.41, 22.14, 20.59, 14.00; HRMS:
(MþH)þ calculated for C34H35N5O7 626.2536; found, 626.2600.
4.9. N-(3-(1-(((3S)-2-Hydroxy-6-oxotetrahydro-2H-pyran-3-yl)
amino)-1-oxopropan-2-yl)-1-isopropyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)
benzamide (39) prepared in 6 steps
4.9.1. (S)-2-(((Allyloxy)carbonyl)amino)-5-(tert-butoxy)-5-oxo-
pentanoic acid
To a cooled (4 C) solution of L-glutamic acid 4-tert-butyl ester
(15.0 g, 73.8mmol) in THF/H2O (45mL/135mL) were added sodium
bicarbonate (24.8 g, 295.2mmol) and allyl chloroformate (14.12mL,
132.8mmol). After 3 h of stirring at room temperature, the medium
was acidified with aqueous HCl (6 N) until obtaining pH 2. The
aqueous layer was extracted (EtOAc). The organic layer was dried
over sodium sulphate, filtered and concentrated under reduced
pressure. The residue was dissolved in saturated aqueous sodium
bicarbonate. The aqueous layer was extracted (EtOAc). The organic
layer was washed with saturated aqueous sodium bicarbonate. The
basic layers were combined, acidified with aqueous HCl (6 N) until
obtaining pH 2 and extracted (EtOAc). The organic layer was dried
over sodium sulphate, filtered and concentrated under vacuum to
afford the title compound (19.7 g, 93%) as a colorless oil: 1H NMR
(CDCl3, 500MHz) d 5.95e5.87 (m, 1H), 4.58 (m, 2H), 5.49 (br d,
J¼ 7.5 Hz, 1H), 5.23e5.20 (m,1H), 5.32e5.29 (m,1H), 4.39e4.36 (m,
1H), 2.47e2.42 (m, 2H), 2.23e2.17 (m, 1H), 2.03e1.95 (m, 1H), 1.44
(s, 9H).
4.9.2. tert-Butyl (S)-4-(((allyloxy)carbonyl)amino)-5-(methoxy-
(methyl)amino)-5-oxopentanoate
To a cooled solution of (S)-2-(((allyloxy)carbonyl)amino)-5-
(tert-butoxy)-5-oxopentanoic acid (19.7 g, 68.5mmol) in DCM
(390mL) were added N,O-dimethylhydroxylamine hydrochloride
(8.02 g, 82.2mmol), 4-methylmorpholine (9.04mL, 82.2mmol) and
1,(3-dimethylaminopropyl)-3-ethylcarbodiimide hydro-chloride
(15.7 g, 82.2mmol). After 3 h of stirring at room temperature, the
mediumwaswashedwith aqueous HCl (1 N), with brine, dried over
sodium sulphate, filtered and concentrated in vacuo. Purification of
the residue by chromatography on silica gel (cyclohexane-EtOAc,
gradient of 9/1 to 6/4) afforded the title compound (16.5 g, 72%, as
colorless oil): 1H NMR (CDCl3, 500MHz) d 5.86e5.93 (m, 1H), 5.48
(br d, J¼ 8.5 Hz, 1H), 5.31e5.27 (m, 1H), 5.21e5.18 (m, 1H),
4.75e4.70 (m,1H), 4.57e4.50 (m, 2H), 3.77 (s, 3H), 3.20 (s, 3H), 2.31
(t, J¼ 7.5 Hz, 2H), 2.06e2.00 (m, 1H), 1.89e1.84 (m, 1H), 1.42 (s, 9H).
4.9.3. tert-Butyl (S)-4-(((allyloxy)carbonyl)amino)-5-
oxopentanoate
A solution of lithium aluminium hydride (2 N in THF, 4.92mL,
9.8mmol) was added dropwise to a cooled (78 C) solution of
tert-butyl (S)-4-(((allyloxy)carbonyl)amino)-5-(methoxy-(methyl)
amino)-5-oxopentanoate (5.0 g, 15.1mmol) in anhydrous THF
(67mL). The mixture was stirred at 78 C for 3h30, then aqueous
HCl (1 N) was slowly added to the medium, and the temperature
was allowed to warm to 0 C. The mixture was diluted with EtOAc.
The aqueous layer was extracted (EtOAc, two times). The combined
organic layer was washed with aqueous HCl (1 N), with brine, dried
over sodium sulphate, filtered and concentrated in vacuo to afford
the title compound (4.27 g, quantitative, as yellow oil): 1H NMR
(CDCl3, 500MHz): d 9.59 (s, 1H), 5.95e5.87 (m, 1H), 5.50 (br s, 1H),
5.31 (d, J¼ 17Hz, 1H), 5.23e5.21 (m, 1H), 4.58 (d, J¼ 5.5 Hz, 2H),
4.31e4.28 (m,1H), 2.40e2.26 (m, 2H), 2.25e2.21 (m,1H), 1.93e1.86
(m, 1H), 1.42 (s, 9H).
4.9.4. tert-Butyl (S)-4-(((allyloxy)carbonyl)amino)-5,5-
diethoxypentanoate
To a freshly prepared solution of tert-butyl (S)-4-(((allyloxy)
carbonyl)amino)-5-oxopentanoate (4.27 g, 15.7mmol) in absolute
ethanol (25mL) were added, under Argon atmosphere, triethyl
orthoformate (15.7mL, 94.4mmol), p-toluenesulfonic acid (81mg,
0.47mmol) and 3Å molecular sieves. After stirring at room tem-
perature overnight, themixturewas filtered over a pad of Celite and
rinsed with EtOH. The filtrate was concentrated under reduced
pressure and co-evaporated with toluene (three times). Purification
of the residue by flash chromatography on silica gel (cyclohexane-
EtOAc, gradient 9/1 to 8/2) afforded the title compound (4.40 g,
81%, as pale yellow oil): LCMS (tR¼ 3.63min, purity¼ 98%), ESIþm/
z 300.1 (M-OEt)þH)þ; 1H NMR (500MHz, CDCl3) d 5.95e5.83 (m,
1H), 5.30 (dq, J¼ 17.2 Hz and 1.6 Hz, 1H), 5.19 (dq, J¼ 10.4 Hz and
1.4 Hz, 1H), 4.90 (d, J¼ 9.5 Hz, 1H), 4.55 (m, 2H), 4.36 (d, J¼ 2.8 Hz,
1H), 3.80e3.74 (m, 1H), 3.73e3.66 (m, 2H), 3.55e3.48 (m, 2H), 2.30
(t, J¼ 7.5 Hz, 2H), 1.96e1.88 (m, 1H), 1.73e1.68 (m, 1H), 1.43 (s, 9H),
1.21 (m, 6H); 13C NMR (101MHz, DMSO‑d6) d 172.03,155.88,133.85,
116.59, 103.03, 79.41, 64.17, 62.79, 61.79, 52.19, 31.42, 27.75, 24.36,
15.26; [a]D20¼25.5 (c ¼ 10 g/L, EtOH); HRMS (MþH)þ calculated
for C17H31NO6 345.2151; found 368.2083 (MþNa)þ, 713.4276
(2MþNa)þ, 244.1206 cyclized warhead eg., (M(-OEt, -C4H9)þ H)þ.
4.9.5. tert-Butyl (4S)-5,5-diethoxy-4-(2-(3-isopropyl-5-(2-methyl-
4-(naphthalen-2-ylamino)-benzamido)-2,6-dioxo-3,6-dihydro-
pyrimidin-1(2H)-yl)propanamido)pentanoate
Step 1: To a stirred solution 2-(3-isopropyl-5-(2-methyl-4-
(naphthalen-2-ylamino)benzamido)-2,6-dioxo-3,6-
dihydropyrimidin-1(2H)-yl)propanoic acid (130mg, 0.26mmol,
1.00 eq.) and pentafluorophenol (52.6mg, 0.29mmol, 1.10 eq.) in a
mixture of DCM (2.6mL) and DMF (1.3mL), was added 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide hydrochloride (54.8mg,
0.29mmol, 1.10 eq.) and the reaction mixture was stirred at room
temperature for 30min.
Step 2: In a separate flask, a solution of (R)-3-
allyloxycarbonylamino-5,5-diethoxy-pentanoic acid tert-butyl
ester (135mg, 0.39mmol, 1.50 eq.) and 1,3-dimethylbarbituric acid
(64.9mg, 0.42mmol, 1.60 eq.) in a mixture of DCM (2.6mL) and
DMF (650 mL) was degassed and purged with nitrogen then tetra-
kis(triphenylphosphine)palladium(0) (12.0mg, 0.01mmol, 0.04
eq.) was added. The reaction mixture was stirred at r.t. for 30min.
Step 3: The solution from the Alloc deprotection containing tert-
butyl (R)-3-amino-5,5-diethoxypentanoate was added dropwise to
the activated ester formed in Step 1 and the resulting solution was
stirred for 2 h at r.t. The reaction mixture was diluted with DCM
(30mL) and washed with a saturated aqueous solution of NaHCO3.
The aqueous phase was washed with DCM (2 10mL). The organic
phases were combined, dried over MgSO4 and concentrated to
dryness. The residue was purified by flash chromatography (silica
gel, gradient of 0e50% EtOAc in heptane) to afford tert-butyl (4S)-
5,5-diethoxy-4-(2-(3-isopropyl-5-(2-methyl-4-(naphthalen-2-
ylamino)-benzamido)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)
propanamido)pentanoate (160mg, 83%) as a beige solid: LCMS
(tR¼ 1.44min, purity¼ 100%), ESIþ m/z 744.46 (MþH)þ; 1H NMR
(DMSO‑d6) d 8.94 (d, J¼ 17.4 Hz, 1H), 8.77 (d, J¼ 4.5 Hz, 1H),
7.77e7.94 (m, 3H), 7.58e7.65 (m, 2H), 7.55 (dd, J¼ 8.5, 1.8 Hz, 1H),
7.48 (t, J¼ 7.5 Hz, 1H), 7.38 (ddd, J¼ 10.4, 7.3, 4.5 Hz, 2H), 7.03e7.16
(m, 2H), 5.29 (qd, J¼ 6.9, 4.4 Hz, 1H), 4.55 (ddd, J¼ 13.4, 7.9, 3.4 Hz,
1H), 3.40e3.71 (m, 4H), 2.50 (d, J¼ 1.9 Hz, 3H), 2.26e2.40 (m, 2H),
1.57e1.86 (m, 2H), 1.49 (dd, J¼ 17.7, 5.9 Hz, 3H), 1.35e1.44 (s, 9H),
1.41 (m, 6H), 1.06e1.22 (m, 6H).
4.9.6. N-(3-(1-(((3S)-2-Hydroxy-6-oxotetrahydro-2H-pyran-3-yl)
amino)-1-oxopropan-2-yl)-1-isopropyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)
benzamide (39)
To a stirred solution of (S)-5,5-diethoxy-4-(2-{3-isopropyl-5-[2-
methyl-4-(naphthalen-2-ylamino)-benzoylamino]-2,6-dioxo-3,6-
dihydro-2H-pyrimidin-1-yl}-propionylamino)-pentanoic acid tert-
butyl ester (105mg, 0.14mmol, 1.00 eq.) in DCM (3.15mL) was
added trifluoroacetic acid (3.15mL, 41.1mmol) at 0 C and the re-
action mixture was stirred at room temperature for 2 h. The reac-
tion mixture was treated with a saturated aqueous solution of
NaHCO3 (aq) to bring the pH to 5 and extracted with DCM
(2 5mL). The organic phases were combined, dried over MgSO4
and concentrated to dryness. The crude product was purified by
flash chromatography (silica gel, gradient of 0e10% MeOH in DCM).
After concentration of the fractions to dryness, the gum was trit-
urated in EtOAc and the solid was collected and dried in a vacuum
oven at 40 C to afford N-(3-(1-(((3S)-2-hydroxy-6-oxotetrahydro-
2H-pyran-3-yl)amino)-1-oxopropan-2-yl)-1-isopropyl-2,4-dioxo-
1,2,3,4-tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-yla-
mino)benzamide (32.0mg, 35%) as a pale pink solid: LCMS
(tR¼ 5.57min, purity¼ 93%), ESIþ m/z 612.35 (MþH)þ; 1H NMR
(DMSO‑d6) d 12.18 (s, 1H), 9.40 (d, J¼ 17.4 Hz,1H), 8.94 (d, J¼ 5.6 Hz,
1H), 8.72 (s, 1H), 8.42 (s, 1H), 7.72e7.88 (m, 3H), 7.58 (d, J¼ 2.2 Hz,
1H), 7.50 (d, J¼ 8.5 Hz, 1H), 7.43 (t, J¼ 7.5 Hz, 1H), 7.27e7.38 (m,
2H), 7.05 (dd, J¼ 18.0, 5.4 Hz, 2H), 5.40 (p, J¼ 6.8 Hz, 1H), 4.78 (td,
J¼ 6.8, 3.2 Hz, 1H), 2.44 (s, 3H), 2.15e2.33 (m, 2H), 1.96e2.02 (m,
1H), 1.77e1.60 (m,1H), 1.45 (d, J¼ 6.9 Hz, 3H), 1.33 (q, J¼ 7.4, 6.4 Hz,
6H); 13C NMR (101MHz, DMSO‑d6) d 169.60, 167.47, 159.04, 156.32,
149.35, 145.38, 145.04, 140.15, 134.26, 131.60, 129.56, 128.99, 128.72,
127.50, 126.52, 126.40, 123.46, 120.60, 118.21, 113.60, 111.53, 112.81,
100.54, 95.21, 58.72, 58.29, 58.04, 20.93, 20.69, 20.57, 13.95, 13.87;
HRMS: (MþH)þ calculated for C33H35N5O7 614.2536; found
614.2603.
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